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1. Introduction
Inhaled therapy for medicinal purposes was used 
at least 4,000 years ago, but using antibiotics in a 
pulmonary dosage form takes back to 1948, when 
Abbot Laboratories developed the Aerohalor for 
the inhalation of Penicillin G powder [1]. However, 
large-scale therapeutic advancement dates back to 
1997, when tobramycin for inhalation was ap-
proved by the U.S. Food and Drug Administration 
(FDA) for use in patients with cystic fibrosis [2]. 
Respiratory tract infections affect people in all 
ages and are very common [3-5]. Globally, infec-
tions of the lower respiratory tract are among the 
top three major causes of morbidity and every 
year, these can be responsible for approximately 
3.5 million deaths in the world [6]. The most com-
mon treatment for respiratory infections involves 
the oral or parenteral administration of high doses 
of single or combined antibiotics, which can show 
undesirable side effects because of high systemic 
bioavailability [7, 8]. The ability to deliver thera-
peutic agents to the site of action may allow effi-
cient treatments of infectious diseases of the respi-
ratory tract and has many advantages over other 
routes [9]. 
The large surface area of the lungs is supplied 
by the excessive blood capillary network, which 
plays a role in the rapid absorption of the drug in 
the lungs. So the absorbed drug can directly reach 
the blood circulation, thus evading first pass me-
tabolism through this non-invasive drug delivery 
system [10, 11].
Therefore, the delivery of even low concentra-
tions of antibiotics to the lungs at the site of infec-
tion leads to much higher concentrations of antibi-
otics in the lungs, while reducing systemic expo-
sure and the risk of toxicity, and yielding thera-
peutic effects with smaller drug doses than the 
oral or parenteral route [12, 13].
One example is when an aminoglycoside antibi-
otic amikacin is given by IV administration, the 
drug concentration in the serum is three times 
higher than in the bronchial tissues, however, 
when amikacin is given by inhalation, drug con-
centration is 1000 times higher in the bronchial tis-
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Abstract
Respiratory infections cause an extensive health problem in the world. The common treatment for respiratory infections is the admin-
istration of antibiotics orally or parenterally in a high dose. Unfortunately, these therapies of high-dose antimicrobials have many dis-
advantages, such as severe side effects. Consequently, the development of an inhaled formulation provides the delivery of the therapeu-
tic dose of the drug to the organ of interest without overt systemic effects. Novel technological advances have led to the development of 
inhaled antibiotics. Recent particle engineering techniques for dry powder inhalers (DPI) or mesh nebulizers have higher aerosoliza-
tion efficiencies and promote the delivery of high-dose antibiotics to the lungs. However, advanced formulation strategies are in high 
demand for the development of new formulations for more types of antibiotics. Despite all the current research, patient compliance with 
pulmonary dosage forms remains to be very low because of the inappropriate administration techniques. Hence, this review focuses on 
three key aspects of the pulmonary dosage forms of antibiotics; the marketed products, the formulation approaches under research and 
innovative formulation strategies for achieving drug delivery through the respiratory tract.
Key words: antibiotic dosage form, Inhaled formulation, dry powder inhalation, nebulization, particle design, antibiotic combina-
tion, ishikawa diagram
44 Acta Pharmaceutica Hungarica DOI: 10.33892/aph.2019.89.43-62
sues than in the serum [14]. The other advantage 
of using a pulmonary dosage form of antibiotics in 
the treatment of chronic infections is that it is not 
associated with pain and it increases patient com-
fort and compliance, causing rational treatment 
outcome. Therefore, it enhances the quality of life, 
shortens the hospitalization period and significant-
ly decreases morbidity and mortality [15-18].
Currently, there are no drugs available that can 
stop the progression of Chronic Obstructive Pul-
monary Disease (COPD), but inhaled therapies 
have proved fruitful by preventing progression in 
many trials. Previously, many oral therapies were 
available for the treatment of idiopathic pulmo-
nary hypertension, however, new interventions 
are needed to increase patient compliance, which 
may affect disease progression. There has also 
been an increase in the development of aerosol-
ized liposomal formulations for the treatment of 
pulmonary neoplasia and 9-nitro-20(S)-camptoth-
ecin liposomal therapy has already been in clinical 
trials [19].
In spite of the great advantages of pulmonary 
dosage forms of antibiotics for the treatment of re-
spiratory infection, there are a few disadvantages 
for this route, which cause limitations when using 
antibiotics in a pulmonary dosage form [20]. Met-
abolic enzymes found in the lungs metabolize the 
antibiotics, however, the pathways and metabolic 
activities are different from degradation observed 
in the gastrointestinal tract [21]. Antibiotics can be 
cleared by the activity of alveolar macrophages 
found in the pulmonary alveoli, and the activity of 
these macrophages is relatively high since they 
are located at one of the extensive borders be-
tween the body and the outside environment [22, 
23]. On the other hand, the inhalation of antibiot-
ics may cause severe local irritation, wheezing, 
bronchospasm and coughing in patients [24].
In consideration of all these advantages and 
disadvantages, the development of inhaled antibi-
otics to treat lung infection is a largely active field, 
with four approved products in the USA and oth-
ers in the late stages of clinical progress [13].
In this review, we have discussed the pulmo-
nary dosage forms of antibiotics for the treatment 
of respiratory infections. Then particular inhaled 
formulations have been reviewed, highlighting 
fields where further research is required, e.g., par-
ticle engineering and particle preparation, and in-
novative formulations of pulmonary dosage 
forms. Then different methods of liposome prepa-
ration of antibiotics have been reviewed, and fi-
nally some of the formulations which contain a 
combination of antibiotics have been studied.
2. Inhaled antibiotic formulations in the market 
and in the development phase
2.1. Approved antibiotic formulations and their 
delivery routes 
The comparison of the general treatment guide-
line of respiratory tract infections and literature 
data about the pulmonary dosage form of antibi-
otics shows that these two lines are not parallel. 
The data show most research and investigations 
of pulmonary dosage forms of antibiotics focus 
on the treatment of cystic fibrosis rather than gen-
erally on the treatment of respiratory tract infec-
tion [25-27]. Cystic Fibrosis (CF) is an inherited 
disease caused by different mutations of the 
transmembrane conductance regulatory gene, 
and consequently respiratory failure follows after 
the chronic inflammation of the respiratory tract 
[28-30]. Currently, CF is the particular pulmonary 
infectious disease in which inhaled antibiotics 
have received FDA and European Medicines 
Agency (EMA) approval [24]. Future inhaled anti-
biotic trials have to focus on pulmonary diseases 
other than CF with large-scale manufacturing of 
marketed products for treating the variety of pul-
monary infections. Hence, the pulmonary dosage 
form of antibiotics can be used for the treatment 
of upper respiratory tract infections such as phar-
yngitis, tonsillitis, laryngitis, tracheitis, or lower 
respiratory tract infections like acute bronchitis 
and pneumonia often following after common 
cold and influenza [31-33]. Therefore, there will 
be a possibility for eradicating a broad spectrum 
of Gram-positive and Gram-negative bacteria 
from the respiratory system. The antibiotics dis-
cussed in this review have been a subject of re-
search and investigation over the years. Nowa-
days they are under clinical investigation or mar-
keting. Table I illustrates the groups of antibiotics 
in different dosage forms that are present in the 
market. So based on the data of table 1, we can as-
sume that many different oral and parenteral dos-
age forms of antibacterial agents have been for-
mulated; however, as Figure 1 shows, only 0.01% 
of antibiotic formulations exist in pulmonary 
dosage form and 0.04% of the total group of anti-
biotics involves inhaled formulations. Figure 2 
shows the ratio of different products in the USA 
and the UK. 
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Table I Summary of different key formulations of antibiotics in the USA and the UK/Europe. (Compiled from EMA’s 
website: www.ema.europa.eu, FDA’s database: www.fda.gov/home, National Institute of Pharmacy and food website:  
www.ogyei.gov.hu)
Group of Penicillins USA UK/Europe
Amoxicillin Capsule, Chewable tablet, Drops, 
Extended-release tablet, Tablet for 
suspension, Suspension
Oral hard Capsule, Dipersible tablet, Oral 
suspension, Powder for oral suspension, 
Powder for solution for injection and infu-
sion
Ampicillin Injection, Solution, Suspension, 
Powder for solution for injection, 
Capsules
Oral suspension, Powder for solution for in-
jection, Powder for oral suspension, Capsules
Dicloxacillin Capsule, Oral suspension
Carbenicillin indanyl Capsule Capsule
Nafcillin Injection, Infusion
Oxacillin Powder for injection, Infusion solu-
tion, Tablet
Capsule, Powder for solution for injection
Penicillin G Injection, Infusion, Tablet Injection, Infusion, Powder for injection, 
Tablet
Penicillin V Oral solution, Tablet Oral solution, Tablet
Piperacillin Injection, Infusion Injection, Infusion
Ticarcillin Infusion Infusion
Group of Cephalosporins USA UK/Europe
Cefaclor Capsule, Film coated tablet, Paede-
tric drops
Capsule, Suspension, Powder for suspension
Cefadroxil Capsule, Suspension, Tablet Capsule, Granule for oral suspension
Cefazolin Injection Powder for injection/ infusion
Cefdinir Suspension, Capsule
Cefepime Injection
Cefixime Tablets, Suspension Granules for oral suspension, Film coated 
tablets,  Powder for oral suspension
Cefotaxime Injection Powder for solution, Powder for injection or 
infusion
Cefotetan Injection
Cefoxitin Infusion
Cefprozil Suspension, Tablets
Ceftazidime Injection Powder for solution, Powder for injection or 
infusion
Ceftibuten Suspension
Ceftizoxime Injection Injection 
Ceftaroline Intravenous powder for injection Intravenous powder for injection
Ceftriaxone Injection Powder for solution, Powder for injection or 
infusion
Cefuroxime Injection, Infusion, Suspension, 
Tablet
Film-coated tablet, Suspension, Granules for 
suspension, Tablet, Powder for injection or 
infusion 
Cephalexin Capsule, Oral suspension, Tablet Capsule, Oral suspension, Tablet
Group of Carbapenems USA UK/Europe
Doripenem Injection
Ertapenem Injection Powder for concentrate for solution for infu-
sion
Imipenem For injection (combination with 
Cilastatin)
Powder for solution for infusion (combina-
tion with Cilastatin)
Meropenem Powder for injection/infusion Powder for solution for injection/infusion
Group of Monobactams USA UK/Europe
Aztreonam Inhalation, Injection, Infusion Injection 
Group of Tetracyclines USA UK/Europe
Demeclocycline Capsule, Tablet Capsule, Tablet
Doxycycline Capsule, Injection, Delayed release 
tablet, Subgingival controlled re-
lease gel
Capsule, Tablet
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Minocycline Extended release capsule, Extended 
release tablet, Injection, Sublingual, 
Oral microspheres 
Film-coated tablet, Tablet, Capsule
Tetracycline Tablet, Capsule, Suspension, Topi-
cal, Eye ointment
Capsule, Tablet, Eye ointment 
Group of Glycylcyclines USA UK/Europe
Tigecycline Injection Injection
Group of Aminoglycosides USA UK/Europe
Amikacin Injection Injection, Solution for infusion
Gentamicin Cream, Drops, Injection, Ointment, 
Solution, Topical
Drops, Infusion, Injection, Solution for injec-
tion
Neomycin Cream, Drops, Injection, Ointment, 
Solution
Tablet, Drops
Streptomycin Injection Injection
Tobramycin Eye drops, Injection, Inhalation 
solution, Ointment, Powder, Oph-
thalmic Solution
Injection, Infusion, Ointment, Eye drops
Group of Macrolides USA UK/Europe
Azithromycin Injection, Suspension, Tablet, Cap-
sule, Ophthamlic solution, Powder 
for suspension
Capsule, Film coated tablet, Injection, Sus-
pension, Powder for oral suspension, Powder 
for solution for injection
Clarithromycin Extended release tablet, Suspension Film coated tablet, Granules for Oral suspen-
sion, Powder for solution for infusion, Tablet
Erythromycin Capsule, Delayed release tablet, 
Delayed release Capsule, Drops, 
Gel, Infusion, Ointment, Oral sus-
pension, Solution, Infusion, Tablet, 
Topial pad  
Film coated tablet, Gastro-resistant tablet, 
Granules for oral suspension, Oral suspen-
sion, Powder for solution for infusion, Sugar 
free Oral suspension, Tablet
Telithromycin Tablet Film tablet
Group of Fluoroquinolones USA UK/Europe
Nalidixic acid Suspension, Tablet Tablet
Ciprofloxacin Drop, Extended release tablet, injec-
tion, Infusion, Ointment, Suspen-
sion, Solution, Tablet 
Drop, Film coated tablet, Granules for oral 
suspension, Solution for infusion, Tablet
Norfloxacin Drop, Suspension, Tablet Tablet
Ofloxacin Drop, Solution, Tablet Tablet
Levofloxacin Drop, Infusion, Injection concen-
trate, Oral solution, Solution, Tablet
Film-coated Tablet, Solution for infusion, 
Tablet
Moxifloxacin Eye drops, Injection, Tablet Film- coated tablet, Solution for infusion, 
Tablet, Eye drops, injection
Group of inhibitors of folate 
synthesis
USA UK/Europe
Mafenide Cream, Topical Solution Cream, Topical solution
Silver sulfadiazine Cream Cream
Sulfasalazine Delayed release tablet, Oral suspen-
sion, Rectal suspension
Enteric coated tablet, Gastro resistant tablet, 
Oral suspension, Tablet
Sulfisoxazole Suspension (combination with 
erythromycin)
                            
Groups of Inhibitors of 
folate reduction
USA UK/Europe
Pyrimethamine Tablet (combination with sulfadox-
ine)       
Tablet (combination with sulfadoxine)       
Trimethoprim Intravenous, Suspension Suspension, Tablet
Others USA UK/Europe
Chloramphenicol Capsule, Injection, Infusion Capsule, Drops, Ointment
Clindamycin Cream, Foam, Gel, Granules, Injec-
tion, Intravenous, Lotion, Solution, 
Suppository, Suspension, Swab 
Capsule, Cream, Hard capsule, Solution for 
injection, Solution for infusion
Linezolid Injection, Intravenous, Suspension, 
Tablet 
Film coated tablet, Granules for oral suspen-
sion, Solution for infusion
Quinupristin / Dalfopristin Powder for injection                       
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2.2. Approved inhaled antibiotic products 
2.2.1. Monobactams (Aztreonam)
β-lactam compounds are the first antibiotics to be 
discovered and widely used in many treatments. 
In this group, monobactams were developed with 
enhanced effect against aerobic Gram-negative 
bacteria. They are inactive against Gram-positive 
bacteria or anaerobic bacteria. They disrupt the 
bacterial cell wall [34]. The most common mono-
bactam antibiotic is aztreonam [35]. Since abso-
lute bioavailability is very low (about 1%) after 
oral administration, it is necessary for aztreonam 
to be administered intravenously or intramuscu-
larly [36]. This drug is very safe for treating pa-
tients who are allergic to penicillins and cephalo-
sporins [37]. Cayston®, aztreonam for inhalation 
solution, has been approved by FDA and EMA 
[38].
2.2.2. Fluoroquinolones (Ciprofloxacin, Levofloxacin)
Fluoroquinolones are potent antibacterial agents 
which target two enzymes, DNA gyrase and DNA 
topoisomerase IV [39]. Fluoroquinolones are rath-
er well-tolerated and safe antibiotics [40]. Cipro-
floxacin is the most potent fluoroquinolone for the 
treatment of pseudomonal infections associated 
with CF [41]. A liposomal ciprofloxacin formula-
tion for inhalation is currently in clinical trials for 
the treatment of respiratory diseases. Dry powder 
formulations of ciprofloxacin are in the advanced 
development stage [42]. Levofloxacin is an isomer 
of ofloxacin, which can be utilized in a wide range 
of infections due to its broad spectrum of activity 
[43]. Nebulized levofloxacin solution, Quinsair 
240 mg, is now in market [44, 45]. 
2.2.3. Aminoglycosides (Amikacin, Tobramycin)
Aminoglycosides are essential antibiotics in the 
treatment of severe and lethal infections [46]. 
Aminoglycosides exhibit bactericidal activity by 
inhibiting protein synthesis as they bind to the 
30S ribosomal subunit prior to ribosome forma-
tion, therefore causing the misreading of mRNA 
and leaving the bacterium unable to synthesize 
proteins necessary for bacterium growth [47]. Li-
posomal amikacin suspension (Arikayce) for in-
halation has been approved by FDA for the treat-
ment of respiratory diseases [48]. Tobramycin so-
lution (TOBI Novartis) has been approved in the 
USA and Europe. Dry powder inhalation tobra-
mycin (TOBI podhaler) has been approved in the 
USA and Europe [49]. Tobramycin exhibits irre-
versible ototoxicity or nephrotoxicity as side ef-
fects, however, when administered in a pulmo-
Figure 2 Ratio of different formulations in USA (left) and UK (right)
Figure 1 Ratio of the inhaled antibiotic Vs non-inhaled 
antibiotic formulation
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nary dosage form, it does not display these sys-
temic side effects, and it is an affirming study 
showing that systemic toxicity can be minimized 
via pulmonary dosage forms [50, 51].
2.2.4. Colistin
Colistin belongs to the polypeptide antibiotics 
known as polymyxins. Colistin is effective against 
most Gram-negative bacteria. Colistin can be giv-
en intravenously and resistance to colistin is rare 
[52]. Colistin is polycationic and has both hydro-
philic and lipophilic moieties [53]. Colistimethate 
sodium solution (Colomycin) has been approved 
in some European countries. Colistin methanesul-
fonate (Colobreathe) dry powder formulations 
have been approved in the USA and European 
countries. Zhou et al. reports a study which re-
veals that colistin in pulmonary dosage forms 
rarely results in systemic side effects [54-56].
2.2.5. Vancomycin
Vancomycin is a tricyclic glycopeptide antibiotic, a 
large hydrophilic molecule that poorly crosses the 
gastrointestinal mucosa. Vancomycin is effective 
against Gram-positive bacteria [57] and it has be-
come extremely useful because of its effectiveness 
against drug-resistant organisms [58]. Dry powder 
of vancomycin hydrochloride (AeroVanc) for inha-
lation has not been marketed yet but phase I clini-
cal study reported excellent tolerability of this an-
tibiotic in volunteers. So dry powder formulations 
of vancomycin are in the upgrading development 
stage [59].
3. Frequently used antibiotic formulation 
techniques 
There are numerous methods to produce pulmo-
nary drug delivery systems; however, here we 
tried to focus on methods that are mostly used for 
pulmonary dosage forms of antibiotics. 
3.1. Nebulization 
Nebulized antibiotics were used for the treatment 
of respiratory infection in the 1950s [60]. The neb-
ulization of antibiotics is a method for delivering 
therapeutic agents in a liquid form (solution or 
suspension) into the lungs by using nebulizing 
devices. Droplets with a diameter of approximate-
ly 1-5 µm are used for inhalation. This fraction 
can deposit in the large and small airways and the 
alveoli. Droplets larger than 5 µm deposit in the 
upper airways and droplets smaller than 1 µm are 
gradually exhaled again or may get into the sys-
temic absorption [61, 62]. As a routine rule, nebu-
lizers are suggested if the antibiotic cannot be ad-
ministered using other devices [63]. Nebulizers 
are usually used for patients who are critically ill 
or children not able to use handheld devices due 
to the smaller geometry of the respiratory tract as 
well as the lower inhalation flow rates [64]. Nebu-
lizers are also applied for any antibiotic available 
only in liquid form and not stable in any other 
form [65]. In the past, intravenous formulations 
were used to deliver antibiotics with different 
nebulizers for the treatment of serious respiratory 
infections. Intravenous formulations of antibiotics 
may contain additives and preservatives harmful 
to the lungs or not having appropriate osmolality, 
pH and particle size, which can cause airway irri-
tation, cough and bronchospasm [66]. During neb-
ulization, antibiotic liquid aerosols are generated 
by mechanical mechanisms like soft mist inhaler, 
human powered nebulizer or electrical mecha-
nisms such as vibrating mesh technology, jet neb-
ulizer and ultrasonic wave nebulizer [67]. Recent 
advances in nebulizer design have been reviewed 
elsewhere [68]. Conventional jet nebulizers gener-
ally have low drug delivery efficiencies and com-
pared to the other types of nebulizers, noisy 
working and heavy weight are the biggest draw-
backs of the jet nebulizer [69]. These issues have 
been improved by vibrating mesh nebulizers to 
produce aerosols with greater concentration of 
droplets and to reduce their administration time. 
As a consequence, minimal residual volume is ex-
hibited, which in turn yields lower antibiotic 
waste, rapid output and enhanced drug delivery 
efficiencies [70-73]. Pulmonary drug delivery by 
nebulization can also be optimized by digital soft-
ware regulation and performance feedback sys-
tems [74]. Table II enlists some antibiotics de-
signed by nebulization.
3.2. Dry Powder Inhalation
Regarding the possible dosage forms for the pul-
monary delivery of antibiotics, one can use a wide 
variety of formulations, such as dry powder inha-
lation (DPI). DPI formulations have been used for 
patient treatment for more than 60 years, but dur-
ing this period the fundamental formation of DPIs 
has not changed significantly [75, 76]. DPIs have 
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become the first choice of inhaled formulations in 
European countries. DPIs are formulations con-
taining micronized drug particles with an aerody-
namic particle size of less than 5 µm [77]. For ade-
quate deposition to reach the central and alveolar 
parts of the lungs, the optimal size of particles 
should be in the region of 1-5 µm. The most im-
portant approach in designing DPIs is that the 
time required for delivering each dose is short 
and even less than one-third of the time is needed 
for delivering the same dose for nebulization. This 
fact is expected to improve patients’ adherence 
[78, 79]. DPIs of antibiotics are more stable, offer 
ease of administration and have less risk of micro-
bial contamination than parallel liquid formula-
tions [80-82]. DPIs have conventional application 
as a formulation of micronized drug in a carrier-
based system [83]. Because the small particles 
(1-5µm) tend to stick with each other due to high 
surface free energy, carriers such as lactose, man-
nitol and trehalose are used for preventing the ag-
glomeration of particles. These excipients reduce 
the surface energy, overcome cohesive forces and 
adhesive forces, and limit the flowability of API 
particles [83]. That is why the carrier-based system 
is being explored for surface modification and ac-
tive targeting. By an appropriate use of the poly-
mer or lipid carrier, the pulmonary drug delivery 
approach can result in interesting outcomes.
Lactose is the most typical and frequently used 
carrier in DPIs but because of clinical issues, lac-
tose cannot be used for drug delivery to diabetic 
patients and people with lactose intolerance [84-
87]. Mannitol, a hexahydric alcohol, has been fre-
quently used as a carrier for aerosol drug delivery 
[17]. Mannitol is less hygroscopic than lactose 
and gives a suitable sweet aftertaste, which is a 
benefit over lactose and enhances the compliance 
of patients [88]. A therapeutic DPI aerosol for the 
treatment of CF and chronic bronchitis (Bronchi-
tolTM), approved by the FDA and the EMA, con-
tains mannitol as a carrier system [89]. A DPI for-
mulation for the inhalation of ciprofloxacin hy-
drochloride was prepared with different percent-
ages of mannitol as a combination formulation. 
Mannitol improved mucous clearance in the re-
spiratory tract while concurrently treating local 
chronic infection, chronic obstructive pulmonary 
disease and cystic fibrosis [90]. Trehalose dihy-
drate is a disaccharide non-reducing sugar and 
can be used as another carrier. A DPI of trehalose 
microparticles with low water content was suc-
cessfully produced by the spray-drying technique 
[91]. Although trehalose leads to autophagy and 
can be used for the treatment of Huntington’s dis-
ease, Parkinson’s disease or tauopathies, it does 
not exhibit any benefit for the treatment of infec-
tions [92]. Moreover, DPIs of antibiotics usually 
have large therapeutic doses (e.g. between 10 mg 
and 100 mg of antibiotics), thus the carrier causes 
difficulty in the application of the DPI due to the 
increased powder volume and the scaled-down 
use of antibiotics via pulmonary dosage forms 
[93]. For about the last two decades, there has 
been significant research on the design of carrier-
free systems for DPIs [83]. Applying a carrier-free 
system makes the delivery of a high dose of anti-
biotics to the lungs possible by limiting the 
amount of excipient [94]. Carrier-free formula-
tions can be handled by coating particles with lip-
ids, amino acids and polymers by the mechanofu-
sion dry coating process [95,–98]. The drug depo-
sition of DPI in the lungs is essentially controlled 
by its aerodynamic behavior. Currently, the aero-
dynamic properties of DPIs are being improved 
by changing formulation strategy and particle en-
gineering [99]. These strategies are discussed in 
detail in Section 3.3.
Table II Nebulized antibiotics and their clinical impact
Therapeutic agent Method Characteristic excipi-
ent
Clinical/Biopharmaceutical impact
Ciprofloxacin Liposome formula-
tion by membrane 
extrusion method
Hydrogenated soy 
phosphatidylcholine/
cholesterol
Enhanced drug encapsulation/size/
stable release [75].
Ciprofloxacin Liposome formula-
tion by membrane 
extrusion
Polysorbate 20/hydro-
genated soy phosphati-
dylcholine/cholesterol
Enhanced release rate [76].
Ciprofloxacin Liposome formula-
tion by thin film 
method
(DOTAP)*/ (DOPE)** 
(PC)***/ cholesterol
Decreased MICs [77].
Colistin Dry film method Dioleoyl-phosphatidyl-
choline
Enhanced release rate [78].
*1,2-Dioleoyloxy-3-trimethylammonium-propane **1,2-dioleoyl-sn-glycero-3-phosphoethanolamine *** phosphatidylcholine
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3.3. Preparation methods for DPIs
3.3.1. Milling (top down)
Milling involves the breakdown of coarse large par-
ticles into fine particles by the use of mechanical 
force. Wet milling and dry milling are the common 
methods used in the production of pharmaceutical 
products. As the name indicates, wet milling in-
volves the breakdown of large particles while they 
remain suspended in liquid medium. Dry milling 
may be sub-branched into various other forms of 
milling that do not require moisture content during 
the breakdown. Wet milling is often used for drugs 
which have a high residual moisture content [100]. 
The pharmaceutical industry also uses jet milling, 
also referred to as fluid energy milling, for most of 
the pharmaceutical dosage form designs. Jet-milled 
powders are highly cohesive because of the high 
surface energies of the particles. This problem can 
be resolved by adding excipients and carriers. How-
ever, this approach seems unfavourable for high-
dose antibiotics. The great advantage of this meth-
od is that it does not require separation [101-103]. 
The process of milling can lead to a decrease in the 
particle size and moderately reduced crystallinity 
because of the production of amorphous form [104]. 
So particle engineering is a very important key fac-
tor for the production of carrier-free (or with mini-
mum carrier) inhalable powders of antibiotics with 
good aerosolization behavior [105, 106]. Overall, the 
process of milling improves drug dissolution and 
solubility profiles. 
3.3.2. Solvent evaporation method (bottom up)
The other process used commonly is the solvent 
evaporation method. It includes spray-drying, 
freeze-drying, spray freeze-drying, and supercrit-
ical fluid followed by rapid expansion. Spray-dry-
ing is a single-step particle formation process and 
is an appropriate way for particle engineering un-
der a controlled manner for scale-up in industry. 
It is used for the production of dry powder from a 
solution, suspension and emulsion by rapid dry-
ing in the presence of a hot gas [107]. Amorphous 
and crystalline materials may be yielded by spray-
drying depending on feedstock. This method 
gives better control over the particle size and 
shape, yielding powders with a narrow particle 
distribution and low particle surface energy. Fur-
thermore, it creates possibility for the addition of 
excipients to promote the dispersibility of the 
powder, to enhance the stability of the formula-
tion, to improve cellular uptake and to complete a 
formulation with modified drug release. Carrier-
free DPI formulations of ciprofloxacin nanoplex 
were developed by spray-drying and spray freeze-
drying methods. D-Mannitol and L-leucine were 
used as drying adjuvant and aerosol dispersion 
enhancer, respectively. Another example is the 
manufacturing of inhaled tobramycin (TOBI® 
podhaler®, Novartis) [108-110]. PulmoSphere of to-
bramycin can also be prepared by treating an 
emulsion under high-pressure homogenisation 
followed by spray-drying.
Different excipients have different effects on the 
mass, particle size, particle morphology and aero-
dynamic behavior of microparticles [111]. A man-
nitol–leucine combination resulted in better aero-
solization behavior of the therapeutic agent, but 
mannitol exhibited some degree of recrystalliza-
tion. A trehalose–leucine combination shows good 
potential to be used as excipient for the pulmo-
nary delivery of potent antibiotics [109]. Although 
spray-drying is a conventional method to produce 
DPIs, the exposure of heat-sensitive antibiotics, 
e.g. penicillin, to the high temperature of the spray 
dryer (>100℃) is not appropriate. The nano spray 
dryer provides very adequate results for the for-
mulation of heat-sensitive materials in submicron 
particles, with high yields (70% to 90%) related to 
the conventional spray-drying method [112]. 
Freeze-drying works by freezing the therapeutic 
agent and then decreasing the pressure to allow 
the frozen water in the material to sublimate di-
rectly from the solid phase to the gas phase [113]. 
Freeze-drying has been considered as a good tech-
nique to enhance the long-term stability of the mi-
croparticles and nanoparticles of antibiotics [114].
The worldwide rise in mortality rates because 
of antibiotic resistance turned out to be the tough-
est challenge to modern medicine and therapeutic 
agents [115]. Monotherapy with a single antibiotic 
may lead to the development of antibiotic resis-
tance due to newly discovered pathogens, which 
cause resistance to a broad spectrum of antibiotics 
[116]. Hence, combination therapies, containing 
different types of antibiotics, have been intro-
duced to inhibit the development of drug resis-
tance [117]. Antibiotic combinations should be ac-
cording to the synergistic effect of antibiotics and 
should avoid interaction [118]. Cospray-drying is 
the method which can assist in such combination 
therapy to achieve the desired effect. The cospray-
dried combination of ciprofloxacin and doxycy-
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cline hydrochloride (1:1) is suitable for inhalation 
and highly effective against Staphylococcus aureus, 
P. aeruginosa and Streptococcus pyogenes [119]. A 
formulation consisting of highly porous nanopar-
ticles loaded with tobramycin surrounded by a 
matrix composed of amorphous clarithromycin, 
with a median particle size of about 400 nm, was 
synthesized by high-pressure homogenisation. In-
terestingly, the results showed that the formula-
tion of the combination of two antibiotics en-
hanced powder dispersion during inhalation. Lo-
cal drug deposition profiles were almost similar 
for the antibiotics and reached the target site con-
currently. The dissolution rate revealed that tobra-
mycin and clarithromycin dissolve with ease in 
the lungs [93]. A formulation comprising cipro-
floxacin hydrochloride and gatifloxacin (fourth 
generation of fluoroquinolone), prepared by the 
spray-drying method, showed a synergistic anti-
microbial effect in the lungs [120]. 
4. Novel DPI formulation strategies and carriers 
for inhaled antibiotics
4.1. Preformulation and Quality by Design approach
The majority of research and innovation for pul-
monary dosage forms of antibiotics does not 
achieve scale-up and marketing. The main rea-
sons are the lack of feasible process, the inappro-
priate way for the efficient and effective control of 
changes, the inability to achieve reasonable prod-
uct quality, the high cost with a low yield, the in-
ability to predict effects of scale-up on the final 
product, the inability to analyze or understand 
reasons for manufacturing failures, and the large 
number of batch failure. Hence, Quality by Design 
(QbD) is necessary before every laboratory re-
search, new formulation, particle engineering and 
powder formulation [121-124]. 
The pharmaceutical QbD is a systematic path-
way for the development of a new formulation, 
which begins with a predefined formulation and 
indicates product and process understanding and 
process control, based on quality risk manage-
ment [125]. QbD appears to enhance the assurance 
of safe and effective drug supply to the patients, 
and also attempts to significantly improve manu-
facturing quality administration. QbD principles 
have been used to regulate product and process 
quality in industry and have been approved by 
the FDA for the discovery, formulation and devel-
opment of drugs [126]. Table III identifies some of 
the characteristic differences between convention-
al and experimental design QBD approaches.
So QbD ensures better design of products with 
fewer problems in manufacturing and allows for 
the better understanding of how APIs and excipi-
ents affect manufacturing. It also leads to a reduc-
tion in the overall costs of manufacturing, thus 
speeding up  the process of approvals and acceler-
ating scale-up production [127]. The specific de-
sign of the inhaler is very critical in achieving ac-
ceptable airflow to deposit the drug into the thera-
peutically effective region of the lungs [128]. DPI 
dosage form properties can be controlled by ad-
justing the particle size, size distribution, particle 
density, particle morphology and shape [129-131]. 
The Ishikawa diagram in Figure 3 illustrates the 
parameters influencing the quality of DPI prod-
ucts in general, assembling all the influencing pa-
rameters of the aimed DPI product [97].
An amikacin product for inhalation in CF pa-
tients was manufactured by spray-drying the pure 
drug, and the formulation exhibited great respira-
bility and flowability. An experimental design was 
applied on the process in relation to six Critical 
Quality Attributes (CQAs) of the finished product 
and five Critical Process Parameters (CPPs). The 
application of the experimental design was set up 
to achieve amikacin powders with both emitted 
dose (ED) and fine particle dose (FPD), completely 
with high regulatory and scientific references  [132]. 
The dry powder formulations of ciprofloxacin 
hydrochloride were prepared by the spray-drying 
method following the QbD approach. An ad-
vanced quality management method was used to 
predict the final quality of the product in relation 
to the QbD-based theoretical preparatory parame-
ters. Dry powder inhalation formulation tests 
Table III  Differences between conventional and QBD approaches
Characteristic Conventional QbD
Pharmaceutical development Univariate experiments Multivariate experiments
Manufacturing process Fixed Flexible
Process control and control strategy Slow and by initial intermediate 
and end product testing 
Actual time, risk-based controls shifted 
upstream  
Product designation It is based on batch data based on desired product achievement 
(safety and efficacy)
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were then successfully performed in practice 
[133].
4.2. Novel formulations and carriers for antibiotics
4.2.1. Microparticles
DPI formulations are usually comprised of mi-
cronized drug powder. One of the highest signifi-
cant upgradations, in powder technologies from 
the micronization of large drug crystals into a re-
spirable range for use in DPIs, is enhancing their 
dispersibility by the reduction of interior adhesive 
forces in the crystals [105]. Pharmaceutical indus-
tries have high demand for crystalline pharma-
cons. Most products for pulmonary dosage forms 
in the market are being manufactured in the crys-
talline state.
Crystalline drugs exhibit more stability; and for 
formulation development, thermodynamically 
stable polymorphs are selected. Salts are selected 
for their better solubility, purity and crystallinity 
relative to the neutral form [134]. For example, a 
DPI formulation was prepared with the sonicated 
solution of ciprofloxacin in acetone because of the 
very low solubility of neutral ciprofloxacin. In 
this formulation, L-leucine was used as a charac-
teristic excipient [135]. In another DPI formula-
tion, ciprofloxacin hydrochloride was used and 
the formulation preparation did not require a tox-
ic organic solvent and a complicated method due 
to the high solubility of the salt form in water. A 
great advantage of the second formulation is that 
L-leucine can dissolve in water easily, too. In both 
cases the DPI showed excellent aerodynamic be-
havior with a fine particle fraction (FPF) value of 
more than 80% [133].
The conventional method of drug powder for-
mulation in the microsized range involves crystal-
lization followed by milling to reduce the particle 
size and to attain the suitable size. This method is 
not an appropriate method as it implies incom-
plete control over the particle size, size distribu-
tion, particle morphology and crystallinity. Muco-
adhesive microparticles are able to swell and hy-
drate after deposition in the lung epithelial cells 
[136, 137]. The encapsulation of ciprofloxacin in 
chitosan is one such example, as the polymer has 
Figure 3 Ishikawa diagram for DPI formulation in general
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swelling properties along with biodegradability 
and biocompatibility characteristics, and antibac-
terial and anti-inflammatory properties. Addition-
ally, these swelling microparticles possess bioad-
hesive properties, promoting adhesion to the pul-
monary system and enhancing antibacterial effect 
[136, 138].
For the microparticles to maintain sustained lo-
cal antibacterial effect, they should avoid phago-
cytosis by alveolar macrophages. The particle size 
range that is optimal for pulmonary inhalation 
(1–5 µm) is also optimal for phagocytosis [139, 
140]. Large porous microparticles, with low densi-
ty but large geometric diameters, display ideal 
lung deposition profiles and can overcome phago-
cytosis challenges [141-143]. Spray-drying is gen-
erally used with different excipients like dipalmi-
toyl-phosphatidylcholine (DPPC) and albumin to 
produce large porous microparticles [144, 145]. 
Also, large porous microparticles can be produced 
by treating solid microparticles with supercritical 
CO2 [146, 147]. Another interesting method for the 
production of large porous microparticles is the 
application of ammonium bicarbonate as an effer-
vescent porogen, which decomposes into ammo-
nia and carbon dioxide in an acidic aqueous solu-
tion or at high temperature  [148].
Porous particles of tobramycin and ciprofloxa-
cin produced by the emulsion method followed 
by spray-drying exhibited enhanced and satisfy-
ing flowability and aerosolization performance 
[149, 150]. A simple double-emulsion method us-
ing poly(DL-lactide-co-glycolide) polymer result-
ed in large porous biodegradable microspheres of 
capreomycin for pulmonary drug delivery. The 
morphology of particles displayed a highly po-
rous interior and an outer rough surface [151].
4.2.2 Nanoparticles
Nowadays, nanoparticles are being widely inves-
tigated for antibiotic inhalation therapy [152], 
however, the formulation of nanoparticles for 
drug delivery application came to the fore in the 
1960s [153]. The considerable advantage of 
nanoparticle formulations is that they  improve 
the solubility and dissolution rate of water-insolu-
ble antibiotics [154]. As an example, the nanoparti-
cles of ciprofloxacin exhibited a speedy dissolu-
tion profile compared to the supplied ciprofloxa-
cin powder. Besides, this formulation of nanopar-
ticles of antibiotics enhanced the Minimum Inhib-
itory Concentration (MIC) and antibacterial 
activity. It was also observed that amikacin 
nanoparticles exhibit MIC and a bacteriostatic ef-
fect against P. aeruginosa compared to less than 
half of the values for free amikacin [155, 156]. Due 
to their small size and large surface area, the 
nanoparticles of the antibiotic showed significant 
and enhanced aerodynamic behaviour. An exam-
ple of tobramycin nanoparticles can be noted 
where the formulation exhibited an FPF of 61% 
compared to the microparticles of tobramycin 
with an FPF of 36% [157].
On the other hand, nanoparticles act as foreign 
materials, with special physiochemical properties, 
in human bodies and are recorded to have severe 
adverse effects on the lungs, like inflammation, fi-
brosis and mutations along with oxidative stress. 
Further, these damages could cause pulmonary 
diseases and diseases in the other parts of body 
[158]. Inhaled nanoparticles can be exhaled be-
cause of their extremely low mass. These prob-
lems have been rectified by formulating nanopar-
ticles into inhalable microparticles into a matrix or 
carrier system. These matrices can be synthetic 
polymers such as PVA, PVP and PLGA; amino ac-
ids like L-leucine; or polysaccharides such as chi-
tosan and sodium hyaluronate [159-161].
4.2.3. Solid lipid microparticles and solid lipid 
nanoparticles
The incorporation of lipid into formulations 
brought about the development of porous parti-
cles with low density [162, 163]. There are various 
methods which have been reported for the syn-
thesis of solid lipid microparticles (SLM) and solid 
lipid nanoparticles (SLN) [164]. Some of these 
methods are double emulsion solvent evaporation 
with freeze-drying [165], high pressure homoge-
nization followed by spray-drying [166-168], melt 
emulsification followed by spray-drying [169], 
melt emulsification followed by freeze-drying 
[170, 171] and simple spray-drying [144]. SLNs usu-
ally have a spherical shape consisting of a solid 
lipid bulk stabilized by a surfactant. Biological 
membrane lipids such as phospholipids, and ste-
rols (cholesterol) can be applied as stabilizers [172]. 
The most important advantages of SLNs from the 
pulmonary perspective include the possibility of 
large-scale production and ability of the incorpo-
ration of lipophilic and hydrophilic drugs, lack of 
biotoxicity of the carrier, high loading capacity, 
drug target delivery and controlling drug release 
[173].
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4.2.4. Liposomes
Discovered by Dr. Alec Bangham in 1961 [174], li-
posomes seem to be a relevant and useful choice 
for pulmonary drug delivery considering their 
preparation from components compatible with the 
lungs, with a good safety profile. Arikayce is the 
first liposomal preparation clinically approved for 
pulmonary administration. No marketed inhaled 
liposomal antibiotic preparation was available 
previously [175]. Liposomal formulations of in-
haled antibiotics are considered to be sustained 
drug delivery systems due to their low and slow 
solubility. These formulations prolong the action 
of drug in the infectious part and increase the an-
tibacterial effect. On the other hand, the sustained 
release of antibiotics minimizes dosing frequency 
and thereby enhances patient compliance. Liposo-
mal antibiotics  can also act as targeted drug de-
livery systems [176]. The encapsulation of drugs in 
liposomes also reduces the occurrence of local ir-
ritation as that caused by traditional pulmonary 
dosage forms. Overall, these benefits of liposomal 
formulations make them an appropriate drug de-
livery system for antibiotics. The surface-mannose 
modification of liposomes with mannose pro-
motes the active targeting of macrophages with 
mannose receptors and provides efficient aerosol-
ized liposomal delivery [177].  Liposome formula-
tions can be administered in a liquid dosage form, 
e.g. nebulizer. However, some solid preparations 
prepared by spray-drying or spray freeze-drying 
can be designed as DPIs [178].
Liposomes are formed immediately when lipids 
are hydrated in contact with water and then dried 
afterwards to form spheres.  Generally, in a large 
scale-up process, lipids are first dissolved in an 
appropriate solvent (mixture of water, ethanol 
and the other organic solvent in a different ratio) 
and then rotatory evaporation removes the sol-
vent. A thin layer of lipid film is formed on the 
wall usually in multilamellar vehicles (MLVs) 
[179-181]. Another method is the ethanol injection 
method, in which liposomes are formed after the 
Table IV Different DPI formulations with their therapeutic outcome
Therapeutic 
agent
Method Characteristic Ex-
cipient
Particle size Resulting therapeutic out-
come
Ciprofloxacin 
and
doxycycline
Spray-drying method PVA* Microparticle Controlled release antibiotics 
[94].
Levofloxacin Nanoprecipitation/emulsi-
fication–solvent evapora-
tion methods
PLGA**/PCL*** Nanoparticle Improved antibacterial effi-
cacy [188].
Levofloxacin Emulsification–solvent 
evaporation  method
PLGA**/phosphati-
dylcholine
Nanoparticle Improved antibacterial effi-
cacy [189].
Tobramycin Emulsion/solvent diffu-
sion method
PLGA**/PVA*/
chitosan/alginate/
lactose
Nanoparticle Increased encapsulation effi-
ciency/release rate/lung depo-
sition pattern [190].
Amikacin Solid-lipid coated by sol-
vent diffusion method/
freeze-drying
Sucrose/
Dextrose/Mannitol
Nanoparticle Long-release term/antibacte-
rial efficacy [159] [160].
Ciprofloxacin Sonicating/freeze-drying L-Leucine Nanoparticle Increased the dissolution rate/
improved aerodynamic prop-
erties [139].
Ciprofloxacin 
hydrochloride
Spray-drying L-Leucine/PVA*/
Cyclodextrin
Microparticle Enhanced the aerodynamic 
behaviour [137].
Tobramycin High-pressure homogeni-
sation/spray-drying
Sodium
glycocholate
Mixture of 
micro- and 
nanoparticles
Enhanced lung deposition 
[161].
Ciprofloxacin Self-assembly method Chitosan/PEG Loaded 
nanoparticle in 
micro hydrogel 
particles
Suitable aerodynamic charac-
teristics/sustains drug release 
[140].
Ciprofloxacin Emulsion/spray-drying _____ Microparticle Enhanced tolerability assess-
ments [153].
Ciprofloxacin Anti-solvent precipitation 
method/spray-drying
_____ Microparticle Enhanced aerosol perfor-
mance [191].
*Poly-vinyl alcohol **poly(lactic-co-glycolic acid) ***Polycaprolactone
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injection of the organic phase into the aqueous 
phase and then by applying diafiltration or ultra-
filtration to remove the excess solvent [182, 183]. 
The possibility of encapsulating hydrophilic and 
lipophilic drugs and easy scale-up are major mer-
its of this method.
A few DPI formulations with their therapeutic 
outcomes are mentioned in Table IV.
5. Patient History
The efficacy and tolerability of nebulized antibiot-
ics in trials remain low and only involve a single 
center or are confounded by inadequate patient 
enrollment, poor methodology, failures in stan-
dardizing or reporting delivery methods, and par-
ticle sizes. Different studies have used different 
doses or formulations as well as differing patient 
cohorts. Hence, there is no standardized tech-
nique for the administration of a given aerosol-
ized drug. These factors make the comparison of 
efficiency and tolerability difficult and pose chal-
lenges when trying to standardize this method of 
treatment and in establishing best practice [184]. 
Studies of inhaled antibiotics targeting non-CF 
pathogens for suppression, eradication or prophy-
laxis are scarce [75], and no inhaled antibiotics are 
approved for lungs in non-CF infections, includ-
ing COPD, melioidosis, pneumonic plague, an-
thrax, Q fever, tularemia, and for patients with 
other infections, including non-tuberculous myco-
bacteria. Despite the need, limited ongoing stud-
ies are observed for the dry powder form of van-
comycin assessing the efficacy and safety of sup-
pressive therapy for methicillin-resistant Staphy-
lococcus aureus (MRSA) infection. The only rec-
ommended prophylactic strategy available is the 
chronic prophylaxis to prevent the acquisition of 
S. aureus, which is used primarily in the UK [185].
6. Future perspective and conclusion
Inhalable powders in the form of nanoparticles 
have potential as a treatment option of respiratory 
tract infections. Targeted delivery is possible by the 
optimization of formulation parameters, and new 
nanoparticle formulation strategies that may en-
hance safety, stability, dispersion and deposition. 
Liposomal formulations of inhaled antibiotics 
are advanced drug delivery systems designed for 
sustained drug release and targeted drug delivery 
to the lungs; nevertheless, low stability and diffi-
culty in liposomal DPI production are notable is-
sues. In this field new techniques and strategies 
are necessarily required to overcome the challenge 
of instability of most liposome formulations. 
In the development of combination therapy, it 
is possible to create novel technological methods 
to design a combination of antibiotics in which 
each particle can have several layers made of dif-
ferent antibiotics with different bactericidal activi-
ties. In this way, resistance by bacteria can be re-
duced, and therefore a new dimension to antibiot-
ic treatment can be explored. 
Inhaled antibiotics for the treatment of respira-
tory tract infections have a great and long history; 
however, these therapies focus on CF patients. 
Right now, there is no academic indication for us-
ing inhaled antibiotics for the treatment of non-CF 
patients. Hence, prescriptions for patients with 
non-CF respiratory infection will continue to be 
based on oral or parenteral dosage forms until sci-
entific evidence from progressing clinical trials be-
come available. Literature data concerning non-
cystic fibrosis patients in the next years will ex-
plain much. Pulmonary dosage forms of antibiot-
ics show interesting results due to high drug con-
centrations in the respiratory tract with minimum 
systemic drug exposure. However, the formula-
tion of antibiotics for pulmonary dosage forms is 
relatively complicated. Antibiotics are adminis-
tered in higher doses than the other therapeutic 
agents for asthma or other inflammatory diseases. 
DPIs have also been favored in recent years for the 
delivery of inhaled antibiotics. The particle engi-
neering technique is a key factor to improve inhal-
able formulations that are able to deliver the drug 
with advanced therapeutic effect. Advanced parti-
cle engineering techniques are also being em-
ployed to revise the manufacturing of DPI formu-
lation for delivering antibiotics. Pulmonary deliv-
ery systems for the treatment of viral lung infec-
tions are completely absent, and this area should 
be explored to develop potent antiviral therapies. 
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1. Introduction – Historical review of inhalation 
for drug delivery
The substantial progression witnessed in the de-
velopment of inhalation devices may indicate that 
pulmonary drug delivery is a novel route of ad-
ministration. However, the use of treatments 
through inhalation for therapeutic intents has ex-
isted for thousands of years and has been prac-
tised in numerous civilizations (Figure 1). Four 
thousand years ago, in India, pulverized jimson-
weed (Datura stramonium) and angel’s trumpet (Da-
tura ferox) were mixed with natural ingredients 
such as pepper or ginger and smoked for their 
bronchodilating therapeutic properties, due to 
their alkaloids content [1, 2]. Apart from that, the 
oldest known mention of the use of inhalation for 
therapeutic purposes dated back to 1554 BC and 
was found in the Ebers papyrus. In this Egyptian 
papyrus scroll, a depiction of patients who seem to 
have trouble breathing can be found. Black hen-
bane (Hyoscyamus niger) is put on hot bricks, and 
the vapour generated is respired by the patients 
through a stem of reed attached to a pot placed 
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Figure 1 Timeline of the History of inhalation therapy
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over the burning plant. Hyoscyamus niger’s reme-
dial properties come from its tropane alkaloids 
contents, particularly atropine and its anticholin-
ergic properties [3]. 
In 1100 BC, opium was smoked using pipes and 
incense burners for both therapeutic and recreation-
al purposes in China. This marks one of the most 
notable uses of the pulmonary route of administra-
tion, although Avicenna thoroughly detailed opi-
oids’ toxicity and dissuaded their usage [3].
In 600 BC, a description of the treatment of asth-
ma by therapeutic inhalation was detailed in the 
scriptures of Charaka and Sushruta (notorious In-
dian physicians). Datura stramonium (which con-
tains atropine) was used against asthma symptoms, 
in the form of a cigarette or a pipe. In his writings, 
Charaka also describes steam inhalation and cigars 
(made of several natural ingredients such as the 
paste of turmeric) as asthma therapies [3].
In the second century AD, Galen suggested the 
use of powders of myrrh and nutgall through in-
halation to reduce nasal and chest symptoms [3].
From the Middle Ages most therapies were 
based on the methods developed during the An-
cient Times such as the smoking of opium or Da-
tura stramonium. One of the most groundbreaking 
approaches of the Middle Ages was made by the 
Arab physician Rhazes. He developed a liquid 
mixture of narcotic plants: opium, mandrake, and 
henbane. A sponge was then soaked in the solu-
tion and left to dry. Before surgery, the sponge 
was humidified and placed on the patient’s mouth 
and nose. The patient would then inhale the 
fumes generated by the sponge. These vapours 
produce an anaesthetic effect [3].
With the start of the Industrial Revolution 
(1760-) came significant innovations, notably in 
manufacturing procedures. The respiratory drug 
delivery acquired a particular attention when the 
English physician Philip Stern declared that “the 
only possible way of applying medicines directly 
to the lung is through the windpipe”. The inhalers 
created by Stern and English physician John 
Mudge amplified the popularity of the treatment 
of asthma through the inhalation of pharmaceuti-
cal drugs [1, 4, 5]. As a consequence, various ce-
ramic inhalers were developed. 
When it comes to drug inhalation, the therapeu-
tic aerosol had to be prepared by either the physi-
cian or the patient himself. However, during the 
Industrial Revolution, the discoveries and advanc-
es made allowed for the aerosol to be made by a 
third party and even to be produced on a large 
scale. Furthermore, novel entities and techniques 
were designed, allowing for the active ingredient 
to be isolated, and its safety and potency to be im-
proved. The Industrial Revolution era also marks 
the launch of nebulizers and early versions of dry 
powder inhalers (DPIs) [3].
The early 1900s were marked by the popularity 
of hand-bulb nebulizers delivering adrenaline 
chloride for its bronchodilating properties. In the 
20th century, new types of nebulizers were devel-
oped: the electric and the ultrasonic nebulizers [1].
The period between 1956 and 1986 brought the 
advances of pressurized metered-dose inhalers 
(MDIs) and later the dry powder inhalers which 
are still broadly used presently. The introduction 
of metered-dose inhalers (MDIs) started in 1956 
[1, 2], among the first approved MDIs was the Me-
dihaler-Ergotamine, a device delivering ergota-
mine tartrate for migraine therapy, which illus-
trates the early interest for the therapy of systemic 
conditions through the pulmonary route of ad-
ministration [6]. Supplementary devices were also 
developed to ameliorate the efficacy of the inhal-
ers and to facilitate patient coordination. Two 
DPIs, in particular, marked this period: the Spin-
haler® and the Rotahaler®. The Spinhaler® deliv-
ered 20 mg of sodium cromoglycate [1] from a 
gelatin capsule which is later on pierced by the 
device. The formulation aspects of this inhaler 
shaped the present formulation development of 
DPIs. The Rotahaler® delivered albuterol from a 
capsule which is later halved by the device [3].
The latest period since 1987 (marked by the sig-
nature of the Montreal Protocol eliminating CFC 
propellants) is characterized by a recordbreaking 
advancement in the pulmonary drug delivery with 
the rise of yearly sales from $7 billion in 1987 to 
$36 billion in 2014 [3]. In 2002, the introduction of 
Advair®/Seretide® delivering salmeterol xinafoate/
fluticasone propionate for the treatment of asthma 
resulted in the first multibillion- dollar DPI. An-
other example is the Spiriva® inhaler launched in 
2004, delivering tiotropium. It was the first inhala-
tion drug intended for the treatment of COPD 
(Chronic Obstructive Pulmonary Disease), which 
at the time was an inefficiently treated disease [6].
2. Advantages of pulmonary drug delivery
The pulmonary delivery is an interesting drug de-
livery route for locally acting treatments of lung 
diseases such as asthma. However, owing to the 
scientific development of pharmaceutical formula-
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tions and inhalation devices, pulmonary drug de-
livery plays an important role in delivering drugs 
systemically and treating systemic conditions such 
as diabetes, certain autoimmune diseases and 
some types of cancer [7]. Pulmonary delivery can 
be obtained via oral or nasal routes. However, 
higher drug deposition can be achieved with the 
former way. This can be attributed to the physio-
logical structure of the human lungs. The respira-
tory tract has two distinct parts by function: the 
respiratory zone and the conducting airways [8]. 
According to Weibel’s lung model – which is the 
simplest and widely used model – there are 23 so-
called generations (G) and the trachea (G0) (Figure 2) 
[9]. The evolution starting from the trachea to the 
alveolar ducts can be described by decreased tube 
length and cross-sectional tube area, yet an in-
creased number of tubes. In the lumen, the trachea 
has a width of approximately 2.5 cm while the al-
veolar ducts possess a diameter of only 0.2–0.5 
mm. Thereby the airways have a surface area of 
about 2.5 m2, and that of the alveoli is about 100 
m2. The mouth and nasal cavities, pharynx and 
larynx, also belong to the conducting zone and are 
responsible for carrying the gas to the site of the 
gas exchange, as well as filter, warm up and hu-
midify the inspired air. The gas exchange occurs 
from the respiratory bronchioles (G17) to the alve-
olar sacs (G23) [8, 10].
Due to their physiological properties, namely a 
large surface area beneficial for absorption (100 m2), 
the lungs possess a unique platform for drug de-
livery, whether locally or systematically. This also 
allows a rapid onset of action of drugs. There are 
no food effect or pH problems, and the first-pass 
metabolism can be avoided. Consequently, a de-
creased effective dose can be used, and fewer side 
effects could occur. 
3. Inhalation devices
The painless drug delivery - compared to injec-
tions - could increase the patient’s compliance. 
However, it is necessary to inform them about the 
proper manipulation of the inhalation devices. Up 
to 50% of the patients misuse the inhalers due to 
the incoordination of the inhalation with the actu-
ating element. Three main types of devices are 
available on the market: nebulizers, pressurized 
metered-dose inhalers (pMDIs) and dry powder 
inhalers (DPIs) (Figures 3-5) [8].
Aerosols are solutions or suspensions, where 
the active ingredient (in a liquid or solid- state) is 
suspended in a carrier gas, intending to deliver the 
drug to the alveoli. Nebulizers can transform the 
solution or suspension into small droplets based 
on different working mechanisms (jet, ultrasonic 
and mesh). They consist of a medication reservoir, 
a baffle compressor, a mouthpiece and a facemask. 
The general disadvantages of nebulizers are the 
high cost, difficulty in cleaning the device and the 
fact that drug wastage could occur. Moreover, 
electricity is necessary for the ultrasonic devices. 
On the other hand, they are easy to use, the con-
tamination could be reduced, and they are more 
efficient when it comes to delivering active ingre-
dients which cannot be delivered with the other 
devices. 
Pressurized metered dose inhalers (pMDIs) are the 
most frequently prescribed devices for asthmatic 
or COPD patients. Single-dose and multi-dose de-
vices are accessible on the market, consisting of 
drug concentrate, propellant, metering valve and 
actuator. The main benefit of pMDIs is that the 
aerosol is formed by atomizing the extremely vol-
atile propellant which is used to deliver an exact 
dose within a short treatment time. They are small 
and portable with a dose counter; therefore the pa-
tient can easily follow the therapy. 
Figure 2 Weibel’s lung model (based on [8])
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Soft Mist inhalers (SMIs) are MDIs, which are 
propellant-free. In order to produce an inspirable 
aerosol from a solution, the liquid dose needs to 
have a suitable droplet size. This can be achieved 
through two main methods: a first approach is the 
use of vibrations created by electrical energy (ul-
trasonic and piezoelectric devices). Another meth-
od would be pushing the solution through a noz-
zle using a mechanical 
force. An example of that 
is the Respimat® SMI (Fig-
ure 6), which functions by 
using the mechanical en-
ergy of a string com-
pressed by the patient 
[11, 12]. 
Another example of 
SMIs is the AERx Es-
sence® (Aradigm Corp.) 
which uses a breath-actu-
ated piston system to 
push the solution through 
a nozzle arrangement, 
and a heating system to 
decrease the droplet size. 
A small screen incorpo-
rated to the device pro-
vides visual feedback to 
the patient. AERx Es-
sence® is used for the pul-
monary administration of 
insulin [12-14].
Dry powder inhalers 
(DPIs) are propellant-free 
devices, containing frac-
tionated and a micronized 
powder formulation of 
drugs. When a patient 
uses their inhaler, their in-
spiratory airflow constitutes the principal driving 
force for delivering breathable particles in dry 
powder to the deep lung. DPI devices contain the 
powder formulation, a dose-measuring system 
and a mouthpiece. The main advantages are that 
they are propellant-free, portable and require a 
short treatment time. However, the main disad-
vantages could be the dependence on the inspira-
Figure 3 Types of inhalation devices
Figure 6 Respimat® Soft mist 
inhaler
Figure 4 Examples of conventional pMDIs: Ventolin Evohaler, Serevent Evohaler, Foster, 
and Atimos
Figure 5 Examples of passive DPIs: Breezhaler, Symbicort Turbuhaler, Pulmicort 
Turbuhaler, Handihaler, Foster Nexthaler, Ellipta, and Seretide Diskus
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tory flow of the patient and the particle aggrega-
tion due to humidity [8, 10]. A study using an in-
vitro-in-silico procedure was performed on several 
DPI formulations placed in a highly humid envi-
ronment. This study examined how these DPI for-
mulations could influence a treatment when 
placed in a high humidity environment, alongside 
patients’ wrong storage of the inhalers. The DPIs 
used were Easyhaler® and Novolizer®, both con-
taining budesonide and lactose. It concluded that 
formulations with smaller particle size and a high-
er quantity of excipient fines are more likely to be 
sensitive to humidity, which makes their efficiency 
inconstant after their storage [15]. This is particu-
larly pertinent and problematic, considering that a 
significant amount of patients store their inhalers 
in unsuitable and highly humid conditions [16]:
 − 42% of patients store their inhaler in a bath-
room
 − 21% in their pocket or a handbag
Concerning patients’ errors, there are current 
trends which aim to face this challenge, such as 
smart devices. These devices are developed using 
electronic monitoring systems that can connect to 
other devices or even to an internet network.  The 
goal is to decrease the errors made by both the pa-
tients and the devices, as well as to enhance the 
patients’ compliance with inhalation therapy. 
These devices possess the ability to track the pa-
tients’ adherence, as well as their use of the inhal-
er. The set goals are reached through characteris-
tics such as a reminder which prompts the patient 
to take the dose, or even by providing the patient 
with a guide displayed on the inhaler’s screen ex-
plaining the use of the inhaler step by step [17]. 
There are two different types of smart inhalers: 
“add-on” devices and “originally integrated” de-
vices. An example of the originally integrated de-
vices is the 3M™ Intelligent Control Inhaler by 
3M™ Drug Delivery Systems [18].
4. Appropriate inhaler use and supplementary 
devices
Managing respiratory conditions such as  asthma 
and COPD depends significantly on the proper 
use of the inhaler provided for the therapy. Incor-
rect use of the device or a faulty inhalation rou-
tine can reduce the drug delivery and therefore 
affect the disease control. A study conducted in 
France by Molimard et al. showed that out of over 
3800 outpatients, 76% made a least one mistake 
while using a pMDI [19]. 
Even with the vast choice of devices available 
on the market and their level of precision, deliver-
ing an accurate dose can still be challenging some-
times. Moreover, when incorrectly using a pMDI, 
a poor drug deposition in the lungs occurs, result-
ing in a high oropharyngeal drug deposition [20-
22]. Consequently, spacers (also referred to as 
holding chambers or extension devices) can be 
used. Spacers are supplementary devices which 
improve the performance of an inhaler. They 
work by keeping the medication in an enclosed 
space during the inhalation. The use of a spacer 
added to a satisfactory inhalation technique can 
improve the drug delivery by up to 5-10% [23]. A 
study organized in India showed that out of 300 
patients, 247 (82.3%) made a mistake while using 
their inhaler. Out of these 247 patients, the highest 
number of errors was noted in patients using 
MDIs (94.3%). However, patients who used a 
spacer with their MDIs resulted in a smaller per-
centage (78%). Some of those errors were: “Inhaler 
not shaken” (40%), “Long delay before inhalation” 
(36%), and “Stopping inhalation as the device is 
fired” (32%) [24]. Thus, spacers not only reduce 
oropharyngeal deposition, but they also decrease 
the accuracy demand for the actuation and inhala-
tion while using a pMDI on its own [25]. This is 
particularly advantageous in infants and children 
since they are unable to produce an accurate in-
spiratory manoeuvre or refuse to cooperate. It is 
also recommended to use facemasks, especially in 
infants [22, 23]. Moreover, the use of spacers and 
facemasks is also helpful and convenient for pa-
tients who require medical assistance, such as el-
derly patients with COPD and cognitive impair-
ment [25, 26]. It has to be noted that spacers and 
facemasks are likely to be exposed to contamina-
tion by microorganisms. Since they are exposed 
and get in contact with mucous membranes, it is 
recommended they undergo cleaning, disinfec-
tion, rinsing, and air-drying after each use [27]. 
However, this cleaning procedure required after 
each use is not executed nor supported or en-
dorsed by the manufacturers and the instructions 
leaflets they provide. Even so, it is advisable, at 
the very least, not to share spacers between pa-
tients [28].
In veterinary medicine, - proper use of spacers 
and facemasks can be observed to improve the 
therapy by optimizing the actuation. Since animal 
and human facial characteristics are not similar, a 
facemask constitutes an essential junction between 
the animal and inhalers such as nebulizers or 
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pMDIs [29]. Moreover, contrary to humans, it is 
quite troublesome to control the breathing pattern 
of animals. In horses, for example, it is inconceiv-
able to inquire a voluntary deep breath. Using an 
extension device such as spacers and facemasks al-
lows the adaptation of commercially available hu-
man pMDIs to horses. Nebulizers could also be 
used, but unlike pMDIs with spacers, nebulizers 
permit the deposition of only small amounts of a 
drug in the equine lungs. In this regard, the utiliza-
tion of pMDIs with a spacer in the veterinary prac-
tice is thought to be a great advance [30]. In case 
the horse reacts to the sound of the pMDI’s actua-
tion, there is a possibility for the inhaler to be actuat-
ed in the spacer, away from the horse’s face. The 
chamber can then be placed on the horse’s face, held 
up to the nostril, until the next inhalation. Examples 
of inhaling devices used for horses are Equine Haler 
and AeroHippus. (Figures 7 and 8) [30]. 
5. Inhalation as an alternative delivery route
5.1. Prospects and innovative developments
Inhalation as a delivery route finds its pertinence 
in the advantageous properties of the lungs (high 
permeability, large surface area). Moreover, an el-
evated local drug concentration can be obtained 
through pulmonary delivery, which is then rapid-
ly absorbed through the alveoli, thus allowing a 
fast onset of action while at the same time still 
keeping systemic adverse effects to the minimum. 
The use of inhalation prevents specific gastroin-
testinal issues such as food effects, gut irritability, 
undesired metabolites, and poor solubility [31]. 
Furthermore, due to the absence of the first-pass 
metabolism, inhalation constitutes a great alterna-
tive to drug formulations, which cannot be deliv-
ered orally [32]. In addition, it also represents an 
excellent substitute for drug formulations, which 
are administered through an invasive method. 
Numerous macromolecules present in different 
stages of clinical development are listed in Table I. 
Similarly, examples of various small molecule in-
halation products present in clinical development 
are listed in Table II [33].
There is also a possibility for vaccination 
through pulmonary delivery. Back in 1958 al-
ready, the possibility of vaccination via inhalation 
was suspected: a quite small number of living at-
tenuated Mycobacterium tuberculosis (fewer than 25 
infective units per animal) effectively induced im-
munity against airborne infection with virulent 
bacilli in guinea pigs [34].
Another example of this is Spiros® (developed 
by Dura Pharmaceuticals Inc.), a measles vaccine 
which is administrable using a DPI. Regrettably, it 
Figure 7 Sketches of the veterinary Equine Haler and 
AeroHippus devices
Figure 8 Inhaling mask for horses
Table I Examples of macromolecules in clinical development (based on [33])
Macromolecule(s) Targeted condition
GLP- 1 and insulin Type 2 diabetes
PTH (parathyroid hormone) and salmon calcitonin Osteoporosis
Erythropoeitin Anemia
Interferons Multiple sclerosis
Growth hormone (GH) Growth deficiencies
Plasmid complex gene delivery Hemophilia
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was not successfully marketed. One of its weak-
nesses was that in case of flat batteries, it was 
prone to failure. Besides, the intricacy of the de-
vice led to its expensiveness [1, 35].
A liposomal inhalation formulation has also 
been developed and FDA-approved for Amikacin, 
an aminoglycoside antibacterial drug. Arikayce® 
(ALIS - Amikacin liposome inhalation suspension) 
is a suspension administered once daily using the 
Lamira™ Nebulizer System. Amikacin is encapsu-
lated in small liposomes (with a diameter of ap-
proximately 300 nm) containing dipalmitoylphos-
phatidylcholine (DPPC) and cholesterol in a high 
drug-to-lipid ratio. It is used for the treatment of 
MAC (Mycobacterium avium complex) lung disease 
in a combination treatment for patients for whom 
the standard therapy has not been successful and 
whose substitute therapies are limited or unavail-
able. It has been shown that ALIS considerably 
improved the chances of obtaining sputum cul-
ture conversion when used as an add-on to guide-
lines-based therapy (GBT) compared to the use of 
GBT alone [36, 37].
5.2. Insulin administration through pulmonary 
delivery
Since the discovery of insulin in 1921-1922 at the 
University of Toronto [38], there has been a per-
manent search for a non-injectable yet effective 
route of administration. In 1987, a study was con-
ducted on six diabetic children where semi-syn-
thetic human insulin was administered via the 
pulmonary route using a nebulizer. The conclu-
sion was that the blood glucose control gathered 
was at least as satisfactory as the one obtained fol-
lowing the administration of the regular dose of 
subcutaneous insulin [39]. Nevertheless, it was ac-
knowledged that inhaled insulin had a consider-
ably reduced bioavailability compared to that of 
the subcutaneous insulin. Thus, inhaled insulin 
reached clinical studies only after the delivery de-
vices available, and particle pharmacology 
reached a certain advancement [40].
The oral and the nasal routes have been the most 
researched, but none of them ended up in a sustain-
able product due to the low and inconstant bioavail-
ability. These issues are mostly due to the imperme-
ability of the nasal and gastrointestinal epithelia to 
insulin. This unsuccessfulness led to the investiga-
tion of the pulmonary route since the lungs are nat-
urally permeable to some proteins [41].
Fourteen short studies conducted on both healthy 
and diabetic patients investigated inhaled regular, 
soluble insulin as early as in 1925. Additionally, in 
all studies, a decrease in blood glucose was noted, as 
well as a considerable absorption of insulin. These 
events were obtained without the help of penetra-
tion enhancers. Moreover, despite early stu dies ap-
prehensions concerning variable dosing, it has been 
guaranteed that the inhaled insulin’s variability can 
be equally as good, if not higher than the subcutane-
ously injected insulin [41].
An example of inhalation insulin was Exubera® 
(developed by Pfizer Inc.). It was approved by 
both the FDA (Food and Drug Administration) 
and the EMEA (European Medicines Agency) for 
the treatment of type 1 and type 2 diabetes. It was 
a DPI which operated using blisters of 1 mg or 3 
mg of regular human insulin [40]. The greater part 
of the formulation was insulin (about 60%). The 
excipients present consisted mainly of a stabilizer 
(mannitol) [42]. The device consisted of active 
powder dispersion by pressurized air obtained 
from a hand piston. Unfortunately, it has not been 
successfully marketed due to its cost, but also its 
significant number of operational steps required, 
and its large size. Insulin requires several admin-
istrations, notably in public. Therefore it is highly 
required for the device used to be convenient and 
discreet [1, 43]. In 2007, weak sales and poor ac-
ceptance of the inhaler prompted Pfizer to discon-
tinue the diabetes drug [6, 40].
A new inhaled insulin example is Afrezza®, an 
FDA-approved ultra-rapid acting insulin aiming 
to enhance postprandial glycemic control in dia-
betic patients, inhaled using a DreamBoat™ inhal-
er [44]. The administration of Afrezza® is ensured 
to be secure and effective in type 1 diabetic pa-
tients [45].
Table II Examples of small molecules in clinical development (based on [33])
Small molecule Targeted condition
Dihydroergotamine Migraine
Fentanyl citrate Breakthrough pain in cancer
Apomorphine Male and female sexual diseases
Nicotine Smoking cessation
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6. Drug deposition and absorption in the lungs
Particle deposition is the first step after inhalation. 
It can occur in the lungs by three main mecha-
nisms: inertial impaction, sedimentation and dif-
fusion. Other mechanisms are an interception and 
electrostatic precipitation which are related to the 
particle shape and the electrostatic charges [9, 46]. 
The deposition mechanisms in the lungs are dem-
onstrated in Table III.
Inertial impaction is the principle deposition mech-
anism in the 1-10 generations of the lungs due to the 
elevated air velocity with the turbulent flow. Larger 
molecules (above 5 µm) tend to move out with the 
air stream and impact the wall of the upper airways. 
The properties of particles, such as density and di-
ameter play a significant role in this case. 
Sedimentation is the time-dependent effect on 
the particles with 0.5-5 µm size in the deeper lung 
(bronchi, bronchioles and alveolar region) where 
the velocity decreases.  The gravitational force 
causes the deposition of the particles and is de-
rived by particle diameter, mass, residence time 
and decreased flow rate. Particles of 3-5 µm reach 
the tracheobronchial region with sedimentation. 
Sedimentation and diffusion are expected in case of 
particles with a size of 0.5-3 µm which are able to 
reach the alveolar region.
In the alveolar region, particles with a size 
smaller than 0.5 µm will deposit according to the 
diffusion principle due to the Brownian motion. 
Nevertheless, due to their significantly small size, 
the majority of the particles are exhaled and mere-
ly few of them deposit.
Direct interception is a phenomenon which usu-
ally occurs in case of particles with elongated 
shape in the upper airways, while charged parti-
cles are prone to undergo electrostatic deposition [9].
The fate of particles after inhalation depends on 
the physiology of the patients and the aerosol 
properties of the particles, namely size, size distri-
bution, shape, charge, density and hygroscopicity 
[10, 46]. It is well established (Table III) that the 
size of particles has an important significance in 
the particle deposition. There are two main calcu-
lable parameters which express the aerodynamic 
properties of aerosols: the mass median aerody-
namic diameter (MMAD) and the geometric stan-
dard deviation (GSD). MMAD is a diameter which 
is calculated based on the mass distribution and 
divides particles into two parts: 50% of the aerosol 
is larger, the remaining 50% is smaller.  If the 
MMAD is between 0.5 µm and 5 µm, the aerosol 
is usually considered breathable. The ideal size for 
a deep lung deposition is 2-3 µm. The GSD dem-
onstrates the variance within the particles, in 
which the values of 1 and above 1.2 indicate mo-
no-disperse and hetero-disperse systems [10]. 
Spherical-shaped particles are the most preferred 
and could easily be manufactured. However, elon-
gated particles are gaining attention due to the 
lung penetration of fibers. Generally, low-density 
particles with a  large geometric diameter have 
better aerodynamic properties than high-density 
particles with a small geometric diameter [10]. 
There are strategies to alter the aerodynamic di-
ameter (Dae). These are based on the following 
equation (1), where Deq is the diameter of an 
equivalent volume sphere of unit density,  ρp and 
ρo are particle and unit densities, and X is the dy-
namic shape factor  [47]:
 (1) 
Both large and porous or needle-shaped parti-
cles are presumed to have a smaller aerodynamic 
diameter than their particle size would suggest 
[47]. All of these parameters aside, the surface 
charge and the hygroscopicity are also important 
physicochemical properties. While the surface 
charge of the cell membrane is negative, small 
particles with a positive charge can bind easily. 
However, the mucus layer of  the lung epithelium 
acts as an absorption barrier due to its adhesive 
surface; therefore it may hinder the penetration of 
even charged particles [48]. Hygroscopic materials 
should be formulated carefully in case of DPIs due 
to the proneness to aggregation [46]. 
Table III Deposition mechanisms in the lung (based on [9])
Particle size Mechanism Parts of Respiratory tract
Above 5 μm Inertial impaction Oropharynx and conducting airways
0.5 – 5 μm Sedimentation
Bronchi, Bronchioles and Alveoli
0.5 – 3 μm Sedimentation and Diffusion
Below 0.5 μm Diffusion and Brownian motion Alveolar region
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Drug absorption in the lung is also influenced 
by the physiological environment and clearance 
mechanisms. In the human lung, the dissolving 
medium volume is about 10-30 ml with a pH of 
about 6.6 and consists of 96% water. The remain-
ing 4% are electrolytes and proteins. The drug 
particles should be in a dissolved state in order to 
absorb, otherwise they might get cleared up by 
one of the clearance mechanisms. The principal 
clearance mechanism is the mucociliary clearance 
(MCC) which is derived by the synchronous 
sweeping movement of cilia and mucus on the 
surface of epithelial cells. Their function is the re-
moval of particles from the environment. There-
fore, with the propulsive movement of mucus to-
wards the larynx, the particles will be eliminated 
by swallowing or coughing out, generally within 
24 hours. The other possibility is the alveolar clear-
ance which is a defence mechanism against harm-
ful microorganisms and particles by macrophages. 
Particles with a size between 1.5 µm and 3 µm are 
more susceptible to phagocytosis, and the alveolar 
permeability is decreasing with increasing molec-
ular weight. There is  also a mechanical clearance for 
large particles (above 10 µm) which immediately 
induces coughing, sneezing or swallowing [9]. 
The metabolisms in the lungs are similar to the liv-
er. All of phase I metabolizing enzymes can be 
found in the lung, however, in lower quantities and 
CYP3A5 is expressed abundantly in the lungs [9].  
Figure 9 shows the correlation between the aero-
dynamic diameter (in µm) and the percentage of 
deposition in the lungs. The aerodynamic diameter 
is the diameter of a sphere with the same settling 
velocity as the particle of interest [50]. As mentioned 
before, large molecules with an aerodynamic diam-
eter higher than 5 µm tend to impact on the wall of 
the upper airways and get swallowed. Therefore, 
the particles with an aerodynamic diameter smaller 
than 5 µm are the ones with the highest potential 
for deposition in the lungs. In an aerosol, the ratio 
of these particles is referred to as either the fine par-
ticle dose (FPD) if it is expressed in absolute mass of 
drug in the particles that are smaller than 5 µm, or 
the fine particle fraction (FPF):
 − The FPD is the mass of particles smaller than 5 
µm present within the total emitted dose. 
 − The FPF is equal to the FPD divided by the total 
emitted dose.
The higher is the FPF in an aerosol, the higher is 
the probability of it depositing deeper in the 
lungs. Consequently, present inhaler devices pro-
duce aerosols containing a considerable percent-
age of particles between 1 and 5 µm [49].
7. Formulation of inhalation dosage forms
7.1. Excipients in the pulmonary drug delivery
The International Pharmaceutical Excipients 
Council (IPEC) characterizes excipients as sub-
stances in a pharmaceutical formulation other 
than the active pharmaceutical ingredients which 
“have been appropriately evaluated for the safety 
in order to help processing, manufacturing, pro-
tection, and give support or to enhance stability, 
bioavailability, or patient 
acceptability or to assist 
in product identification 
or improve any features 
of the safety or effective-
ness of the drug delivery 
system during storage or 
use.” [51]. When it comes 
to pulmonary drug deliv-
ery, excipients are partic-
ularly necessary in the 
formulation in order to 
achieve an optimal size, 
for instance. As a conse-
quence, excipients for in-
haled drugs are usually 
present in relatively high 
amounts compared to the 
active pharmaceutical in-
gredient. 
Figure 9 Relationship between particle aerodynamic diameter and lung deposition (based on 
[49])
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7.2. Formulations in the pulmonary drug delivery
As seen previously, the inhalation systems can be 
divided into three main types: nebulizers, pMDIs, 
and DPIs. 
Nebulizers’ formulation consists of sterile water 
combined with co-solvents if needed. It is prefera-
ble to keep the number of excipients present in the 
formulation to a minimum in order to avoid toxic-
ity [9].
The formulation of pMDIs consists of a product 
concentrate, which will be either solubilized or 
dispersed in a propellant using an elevated va-
pour pressure. The formulation itself is quite com-
plex, owing to the presence of both propellants 
and high vapour pressure [9]. Propellants can be 
liquefied compressed gas, compressed gas propel-
lants, or chlorofluorocarbons. However, due to 
their ozone-depleting behaviour, the use of chlo-
rofluorocarbons has been discontinued since Janu-
ary 1st, 1996, following the Montreal Protocol. 
They since have been replaced by hydrofluoroal-
kanes [52].
Out of the three main types of inhalation sys-
tems, DPIs would be the most advantageous type 
due to their propellant-free formulation. Howev-
er, DPIs’ formulation requires the use of micron-
ized drug particles. These particles display poor 
flow properties as well as cohesiveness. Increased 
Van der Waals, electrostatic forces, and surface 
tension between the layers of particles result from 
the high surface area to mass ratio caused by the 
micronized drug particles [9]. Because of this, 
their formulation usually requires the active phar-
maceutical ingredient to be combined with coarse 
and fine carrier particles. This will, in turn, ame-
liorate the flow properties and raise the particle 
aerodynamic behaviour [53].
The particle size of an aerosol plays a crucial 
role in delivering the drug to its target site, hence 
providing an efficient therapy, while simultane-
ously avoiding clearance mechanisms [54]. In fact, 
in aerosol therapy, the particle size is believed to be 
one of the most crucial physical characteristic [30]. 
In horses for instance, similarly as in humans, par-
ticles which are considered to be large (> 10 µm) 
are either separated and filtered in the upper re-
spiratory tract or collected in the larger airways. 
Particles which are considered to be medium-
sized (6-10 µm) will deposit and accumulate in the 
larynx, trachea, bronchi, and large diameter bron-
chioles. Particles which are considered to be small 
(5 µm or less) will deposit in the small-diameter 
bronchioles and alveoli; while roughly half of the 
particles which are considered to be very small 
(< 1 µm) will deposit in the alveoli, while the other 
half will be exhaled [30]. Therefore, powder for-
mulations intended for inhalation generally con-
tain micronized drug particles with a particle size 
between 1 and 5 µm in order to obtain a valuable 
central and deep lung deposition. These drug par-
ticles are usually blended with an inactive excipi-
ent of greater size (40µm). Possible inactive excipi-
ents are: lactose, mannitol, trehalose, sucrose, sor-
bitol, and glucose [55]. Among them, lactose (pre-
cisely a-lactose monohydrate) is the most fre-
quently used carrier owing to its numerous 
advantageous properties such as [56]:
 − Physico-chemical stability and compatibility 
(displayed with most low molecular weight 
drugs)
 − Safe toxicological profile
 − Availability and affordability
Nonetheless, lactose possesses disadvantages as 
well: it cannot be administered to patients who are 
diabetic or lactose-intolerant since it gets ultimate-
ly swallowed by the patient, due to its impact on 
the oropharynx following the device actuation 
[56]. Due to these reasons, mannitol can be used as 
an alternative to lactose [57]. It is also relevant to 
bear in mind that an active pharmaceutical ingre-
dient containing amino groups (proteins, weak 
bases) cannot be present in the same formulation 
as reducing sugars because it would lead to insta-
bility due to the Maillard reaction [58]. In order to 
overcome this, non-reducing disaccharides, non-
reducing polysaccharides (trehalose and raffinose, 
for instance), and other sugars are being investi-
gated as carriers [56].
Moreover, several active pharmaceutical ingre-
dients are highly potent: drugs used for the treat-
ment of diseases such as asthma are already effec-
tive at a low dose. For instance, only 200-400 µg 
for salbutamol and 6-12 µg for formoterol are re-
quired for the drug to be effective [59]. This arises 
issues concerning powder handling as well as pre-
cise metering of doses. In order to overcome those 
issues, carriers can be used.  The carrier material 
should meet requirements such as [56, 60]: 
 − Providing bulk and ensuring flowability
 − Decreasing the agglomeration of the particles
 − Facilitating powder handling and dosing by 
providing a larger volume to the formulation
 − Helping the dispersion of the micronized drug
Moreover, fine lactose particles present within 
an equivalent size range as the active pharmaceu-
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tical ingredient have been identified as an impor-
tant element in order to improve the formulation 
performance [61]. Among the possible explana-
tions for this phenomenon are the presence of ac-
tive sites and the agglomeration of drug and fine 
excipients [62]. Inhalation formulations containing 
a low dose of the active pharmaceutical ingredient 
tend to be more affected by the properties of the 
carrier. This might be due to the occurrence of ac-
tive sites on the carrier as well as their availability 
[60]. The drug/lactose ratio and the aerosolization 
performance are correlated, and this correlation is 
associated with the possible existence of active 
sites on the surface of the lactose carrier [63].
7.3. Carriers suitable for a small particle size
Powders suitable for inhalation are most common-
ly obtained by carrier-based systems which con-
sist of two elements: the drug and its carrier.
The drug is usually mixed with larger, coarser 
lactose particles which act as a carrier and amelio-
rate the dose reproducibility. As the drug and the 
carrier are blended, the micronized drug particles 
attach to the surface of the lactose carrier particles, 
hence forming an adhesive mixture (Figure 10).
Furthermore, interparticulate forces present in 
adhesive mixtures are required to be able to pro-
duce a blend which is stable and homogenous. 
Due to the considerable size difference between 
the drug and its carrier, the unplanned separation 
of the two should be avoided, while still enabling 
an easy detachment of one from the other through 
weak enough drug-carrier interactions. Conse-
quently, the drug delivery occurs through three 
steps [56]: the detachment of the active pharma-
ceutical ingredient from its carrier, their disper-
sion in the airflow, and the deposition in the respi-
ratory tract (Figure 11). In the case of DPIs, the 
powder formulation is present in the capsule in an 
aggregated form with a size of 100-150 µm. In or-
der to disaggregate it, a deep and strong inhala-
tion through the device is required, thus reducing 
it to inhalable particles (1-5 µm) which can suc-
cessfully deposit in the lungs [64]. This de-aggre-
gation process constitutes a fundamental require-
ment for DPIs capsules contents [65].
During the drug/carrier detachment in the first 
step, the fate of the carrier is either to remain in 
the inhalation device or to deposit in the oropha-
ryngeal region. In adhesive drug mixtures, excipi-
ents used as carriers are considered to have a 
“limited” loading capacity, which makes them 
convenient for low drug doses. Classic drug-to-
carrier ratios are 1:67.5 or 1:99 [56]. The drug 
quantity which can be processed is limited due to 
requirements for the content uniformity and sta-
bility [66]. The limit is set to 5-10% of the drug, de-
pending on the excipient used in the formulation 
as a carrier [67].
The use of active pharmaceutical ingredients at 
a low dose such as dry powders is mainly aimed 
for the therapy of respiratory diseases (asthma, 
COPD). In pulmonary drug delivery, the dose of a 
drug used is considered low when it is in the mi-
crogram range (<1 mg) [66]. The drug dose can 
vary from 6 µg (eformoterol 
fumarate: Oxis®) to 500 µg 
(fluticasone propionate: Flix-
otide®, Seretide®) [68].
8. Tests and characterization 
of aerosols
8.1. Tests
As seen previously, the for-
mulation of inhalation dosage 
forms plays a great role in 
their efficiency and is there-
fore quite elaborated. The 
processes it involves are com-
plex; thus thorough testing is 
necessary to ensure the safety 
and quality of the end prod-
uct. Table IV displays the gen-Figure 10 Adhesive mixture formation
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Figure 11 Illustration of the steps in the drug delivery of carrier-based formulations
Table IV Aerosol devices and formulations tests (based on [9, 69])
Test Description
Dose uniformity −− Assay of the material or the solvent onto which the dose is sprayed.
−− Firstly, an empty container is weighed. Secondly, a certain number of doses are sprayed in this 
same container, which is then weighed again. The difference in weight is then calculated, and 
divided by the number of doses sprayed. 
Particle size 
determination
The determination is done using a cascade impactor or using a light scattering decay method. 
The particle size is expressed in µm.
Moisture content The test can be done by Karl-Fischer or by gas chromatography. The moisture content is ex-
pressed in %.
Density The test can be done using a hydrometer or a pycnometer. A pressure tube is fitted with a Hoke 
valve, metal fingers, and a hydrometer placed into it. The sample is then put in through the Hoke 
valve. This causes the hydrometer to elevate in the pressure tube at half height. The density can 
then be read and is expressed in g/ml.
Vapor pressure The test can be done by pressure gauge. The pressure variation between containers indicates the 
presence of air in the headspace. Vapor pressure can also be accurately measured using a can 
punctuating device. The vapor pressure is expressed as kPa, bar, atm, or psi.
Spray pattern The aerosol being tested is sprayed on a paper coated with a dye-talc mixture. The dye is either 
water-soluble or oil-soluble. Particles which collide with the coated paper cause the dye to solu-
bilize and get absorbed onto the paper. This gives a definite spray pattern.
Aerosol valve discharge 
rate
Two weights are measured:  W1 and W2.
−− W1: Initial weight of a container
−− W2: Weight of that same container after being actuated for a particular period of time. 
The discharge rate with respect to time is obtained by dividing the difference in weights by the 
time (of the actuation process).
Propellant identification The identification can be done by gas chromatography or infrared spectrophotometry. These 
methods can also be used to determine the composition of a blend of propellants.
The determination of moisture, halogen, and non-volatile residue provide an acceptability and 
purity check of the propellants.
Flammability and 
combustibility  
(Flash Point)
The test requires a Tag Open Cup (TOC) apparatus. The aerosol product is chilled to -25°F 
(= -31.67°C) then transferred to the apparatus. The temperature of the liquid is gradually 
increased. When the liquid’s vapor ignites, the “flash point” temperature has been reached. It is 
expressed in °C.
Flame projection The test measures the extension of a flame length when the aerosol product is sprayed on an open 
flame for about 4 seconds. A ruler is used to measure the extension of the flame, and the result 
is expressed in cm.
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eral and additional evaluation tests done on aero-
sols and their formulation [9, 69].
Characterization of the performance of DPIs 
can be done using two aspects: the patient’s inspi-
ratory flow and the turbulence generated inside 
the inhaler itself. Since DPIs are breath-actuated 
devices, the powder formulation they deliver re-
quires the patient to supply turbulent inspiratory 
forces to break down the powder aggregates into 
fine particles of less than 5 µm in diameter in or-
der for them to deposit deeper in the lungs. As 
mentioned before, optimal use of the dry powder 
inhaling device is determined by the patient pro-
viding an appropriate inspiratory flow, and the 
turbulence generated by the intrinsic resistance of 
the inhaler, which is influenced by the design of 
the device. Basically, three varieties of designs are 
available, with a low (such as the Breezhaler®), 
medium (such as the Ellipta®), or high resistance 
(such as the Handihaler®). The duplicability of the 
dose by the device at different flow rates demon-
strates how the incorrect manipulation of the in-
haler affects the system. The higher the inspirato-
ry flow, the better the performance of the device 
since the drug dose inhaled by the patient is in-
creased [70, 71]. A favourable peak inspiratory 
flow rate should be of minimum 60 L/min through 
the inhaler to achieve disaggregation of the pow-
der formulation. The device-specific airflow resis-
tance is determined using the pressure drop and 
the flow rate following Ohm’s law, as shown in 
equation (2) [72]. Higher airflow resistance is as-
sociated with more considerable difficulties for 
patients (particularly in children and elderly peo-
ple) to adequately operate the device with an ap-
propriate flow rate, which makes the airflow resis-
tant a significant parameter [70].
 (2) 
where  R = Resistance, ΔP = Pressure drop, 
Q = Flow rate.
Oxis Turbuhaler® and Foradil Aerolizer® DPIs 
have been tested in vitro to study their efficiency in 
delivering 12 µg of Formoterol fumarate, a 
β2-sympathomimetic drug, and 600 µg of lactose 
monohydrate. Four flow rates were investigated 
(28.3, 40, 60, and 80 L/min). The optimum flow rate 
for both inhalers ranges between 40 and 60 L/min 
to deliver a satisfactory bronchodilation effect. The 
study concluded that Oxis Turbuhaler® delivered 
smaller particles; thus a deeper lung deposition 
was achieved. However, the high specific airflow 
resistance is a factor which will affect the usage of 
the device by severe asthmatic children. Neverthe-
less, no difference in their bronchodilating effect 
was found [73].
8.2. Particle size determination
8.2.1. Cascade Impactor
The determination of the therapeutic activity of 
an inhalation aerosol is dependent on the particle 
size [69]. Cascade Impactors are mentioned in the 
Pharmacopeia and therefore constitute the most 
commonly used devices for the in vitro study and 
measurement of the particle size distribution of 
inhaled formulations. This is mainly due to their 
numerous advantages such as the direct measure-
ment of aerodynamic particle size, and the deter-
mination of drug mass in the formulation with 
different size ranges, without the disturbances 
from the excipients [17].
Originally, the Andersen Cascade Impactor 
(ACI) was the most commonly used impactor in 
the pharmaceutical industry. However, the ACI 
displayed certain disadvantages and has since 
been replaced by the Next Generation Impactor 
(NGI), specially designed for inhaler testing [74] 
(Figure 12).
Cascade impactors rearrange particles and drop-
lets in an aerosol based on their aerodynamic diam-
eter. They use particle/droplet inertia impaction to 
segregate particles and droplets from a moving air-
stream [69]. The NGI comprises 7 stages (Figure 
13), 5 of which are in a 0.5-5 microns range. Each 
stage contains a set of nozzles. The airflow moves 
Figure 12 Next Generation Impactor (NGI) with induction 
port and preseparator
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across the apparatus follow-
ing a sawtooth pattern. The 
velocity of the airstream is in-
creased as it is forced to cross 
through a sequence of nozzles 
comprising progressively de-
creasing jet diameters. This re-
sults in particle separation as 
well as sizing [74].
Another particular feature 
of the NGI is also its micro-
orifice collector (MOC). It 
catches highly small particles 
in a collection cup, which can 
be evaluated along with the 
particles collected in the stag-
es cups [75]. Aerodynamic 
properties can be calculated 
from the collected data.
Figure 14 shows the Spiri-
va HandiHaler® placed on the 
induction port of the NGI. 
HandiHaler is an 18 µm/cap-
sule DPI made by Boehringer 
Ingelheim/Pfizer Inc. Its pow-
der is delivered at a flow of 
20-30 L/min, making it a 
flow-limiting device [77, 78].
Figure 15 demonstrates the 
Serevent Evohaler® placed on 
the induction port of the NGI. 
Serevent Evohaler is a 25 µm/
actuation inhaler made by 
GlaxoSmithKline Inc. It is a 
CFC-free pMDI [79].
8.2.2. Laser Diffraction
Particle size analysis can also be performed using 
optical methods as an alternative, such as laser 
diffraction (light scattering), laser Doppler, or 
time-of-flight. The most widely used among these 
is the laser diffraction [17]. The Cascade Impactor 
analysis can be substituted by laser diffraction in 
order to assess the particle size, however, aerody-
namic diameters cannot be measured with this 
technique. Moreover, the main advantage offered 
by NGIs is the determination of the FPF and other 
size fractions. The other methods, such as laser 
diffraction provide no differentiation. It simply 
measures the overall particle size distribution in 
the sample [80]. However, laser diffraction is con-
sidered to be a remarkably accurate, flow rate-in-
dependent and a rather quick method and there-
fore constitutes an excellent alternative for the cas-
cade impactor measurements. This technique has 
been used since the 1980s to measure the particle 
size of nebulized drug solutions [81]. 
The laser produces a monochromatic, coherent, 
parallel beam which is widened by the beam ex-
pander unit (Figure 16). This beam then casts a 
light on the dispersed particles. The light pro-
duced is scattered by the dispersed particles. 
These particles in the measuring zone form scat-
tering patterns and these patterns carry informa-
tion on the number of particles, the particle size, 
and the particle shape in any orientation [82, 83]. 
Examples of laser diffraction instruments are:
Figure 13 NGI stages and micro-orifice collector (MOC) with their number of holes 
and nozzle diameter (based on [75, 76])
Figure 14 HandiHaler placed on the induction port of the NGI
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 −  RODOS for dry dispersions
 − HELOS (Helium-Neon Laser Optical System) la-
ser diffraction sensor which can be connected to 
different inhalers (DPI, MDI, Soft mist inhalers)
 − MYTOS which makes possible the in-line dry 
particle size analysis for automated laboratories
All are developed by Sympatec Inc. They pro-
vide a precise particle size analysis for dry pow-
ders in the size range below  0.1 µm to 4000 µm 
for RODOS, 0.1 µm to 8750 µm for HELOS, and 
from 0.25 µm to 3500 µm for MYTOS [84].
In the case of dry powders, sampling before mea-
suring is a significant step. An ineffective sampling 
technique will result in a wrong characterization of 
the powder. In laser diffraction, powder measure-
ments can be carried out by dry dispersion, which 
aim is to enable the measurement of particles indi-
vidually. This is done through the separation of par-
ticles agglomerates by suppressing the forces which 
bind these particles together. 
This can be achieved using the 
RODOS injection disperser 
(Sympatec Inc.). With RODOS, 
the compressed air injector 
provides an effective, long, and 
straight dispersion line of dry 
solid particles with a special 
flow control which can mix the 
particles with inert gas or com-
pressed air. This high airflow, 
the jet formation and expan-
sion provide an optimal aero-
sol cloud for the optical analy-
sis without aggregation. Mea-
surements directly from the 
aerosol cloud are also possible 
using systems such as HELOS 
(Sympatec Inc.), which pro-
vides a distribution analysis for 
powders and granules, but also 
wet samples such as suspen-
sions, emulsions, and sprays 
[80, 84].
However, this technique 
possesses drawbacks as well: 
the measuring zone lacks a 
suitable air extraction which 
would be required in order to 
prevent the aerosol droplets 
from entering back into the la-
ser beam. Air suction is also 
necessary to analyze how the 
inspiratory flow rate affects 
the droplet size distribution. This shortage is ex-
plained by the fact that a junction is needed be-
tween the nebulizer’s mouthpiece and the vacuum 
system in order to obtain a controlled air extrac-
tion. Nevertheless, it is not easily achievable and 
rather complicated to do so due to interferences 
with the laser beam. Other limitations include [80]:
 − The calculation of volume distribution curves 
presuming that the particles possess a spherical 
shape.
 − The inability to measure aerodynamic diame-
ters (geometric particle diameters are measured 
instead).
 − The inability to acquire fine particle mass frac-
tions.
 − The inability to measure low particle concentra-
tions (dose weights < 4 µg).
 − The inability to control the flow curve through 
the inhalation device.
Figure 15 Evohaler placed on the induction port of the NGI
Figure 16 Laser diffraction particle size analyzer layout (based on [82])
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 − Mixtures measurements (drug-drug or drug-ex-
cipients) are rather difficult.
 − The measuring range is broader than the drug 
particles’ size distribution: a 0.9 µm – 175 µm 
range for a 100 mm lens, and a 0.45 µm – 87.5 µm 
range for a 50 mm lens.
Nonetheless, laser diffraction remains a tech-
nique with several advantages, such as numer-
ous size classes, precision, and a brief measuring 
time.
8.3. Dissolution
The study of adissolution behaviour is the study 
of a solid substance’s potential to penetrate a sol-
vent medium based on affinity characteristics. 
This provides useful information on the sub-
stance’s absorption behaviour in vivo [17].
The dissolution profile of a dosage form consti-
tutes an essential parameter for the bioavailability 
of any drug that is applied by a non-parenteral 
route. Factors that influence the dissolution be-
haviour of a drug include drug solubility, drug 
dose, formulation properties, drug particle prop-
erties, and the epithelial lining fluid (ELF) compo-
sition (which changes along the respiratory tract) 
[85]. In the lungs, the dissolution is the most sig-
nificant in the small bronchioles and the alveoli, 
which constitute the segment where the majority 
of the drug absorption takes place. After inhala-
tion, the fate of the drug particles is to dissolve in 
the ELF present along the respiratory tract. The 
ELF consists of a surfactant layer and an aqueous 
phase [85]. According to the region of the lungs 
where it is situated, the lining fluid differs in com-
position, thickness, and volume: the trachea, bron-
chi, and bronchioles are enveloped with a thick 
mucus gel (approximately 3 – 23 µm) whereas the 
alveolar region is covered with a particularly thin 
film (approximately 0.07 µm). The progressing 
thinning of the ELF results in physiological dis-
similarities, which in turn induce difficulties in es-
tablishing the residence time of the particles by 
simulating lung conditions [86]. After inhalation, 
the particles which penetrate the non-ciliated seg-
ment of the pulmonary region will dissolve in the 
ELF. Only this dissolved portion of the dose ad-
ministered will be accessible for absorption 
through the alveolar membrane [17].
Currently, the pharmacopoeia does not list any 
standard method for the dissolution testing of in-
halation drugs despite the fact that several meth-
ods have been designed [17, 86, 87]. A certain 
number of methods are available to study conven-
tional solid dosage forms, but they are intended 
for the simulation of the gastrointestinal tract and 
are therefore not suitable to study the dissolution 
of inhaled drugs (mainly due to their “sink” con-
ditions”) [17]. An example of these methods is the 
paddle over disc dissolution setup. This method 
enables the evaluation of the in vitro dissolution 
rate of inhaled formulations [88]. Another method 
is the flow-through cell apparatus, which studies 
the dissolution profile of poorly soluble glucocor-
ticoids aerosols [89]. The dissolution profile of in-
haled formulations can also be assessed using the 
diffusion-Franz cell apparatus. A study evaluating 
these three methods (the paddle over disc meth-
od, the flow through cell, and the diffusion-Franz 
cell apparatus) concluded that the Franz cell ap-
paratus was the most promising [17, 90]. The 
Franz cell apparatus consists 
of a donor and receptor com-
partment. These two com-
partments are separated by a 
semi-permeable cellulose 
membrane. The powdered 
formulation is set on the bot-
tom surface of a filter mem-
brane, which is then posi-
tioned on the semi-permeable 
cellulose membrane. The 
drug will then dissolve and 
diffuse through the semi-per-
meable membrane. The study 
is done on samples gathered 
from the receptor compart-
ment. The dissolved drug 
which diffuses through the Figure 17 Franz Cell Model
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membrane is analyzed by collecting the samples 
from the acceptor compartment (Figure 17).
Moreover, developing a method for the dissolu-
tion testing of an inhaled drug applicable to the 
lungs and their physiology can be quite complex 
due to the lungs’ characteristics such as the small 
amount of their fluid. Besides, a separation of the 
API from the excipients should be done before 
testing [17]. However, a recent study developed 
an apparatus aiming to investigate the dissolution 
behaviour of anti-tubercular drugs powder for-
mulations. This apparatus consists of a flow per-
fusion cell which symbolizes the air/blood perfu-
sion. It employs a small volume of  25 µL of un-
stirred, stationary medium to study the in vitro 
dissolution of inhalable drug particles, notably 
moxifloxacin and ethionamide, two anti-tubercu-
lar drugs. The particles of these two drugs were 
set on a sheet glass with the help of a Twin Stage 
Impinger. The mucus in which they should dis-
solve was simulated by polyethylene oxide (PEO) 
in a phosphate-buffered saline (PBS). Their disso-
lution profile was then investigated. The study 
concluded that ethionamide has a lower solubility 
and displayed a slower dissolution rate than 
moxifloxacin under all the dissolution conditions 
applied. The dissolution behaviour of ethion-
amide brought into question the dissolution 
mechanisms in small volumes of stationary medi-
um (simulating the in vivo tracheobronchial region 
of the lungs). Such questions could be addressed 
using this method [17, 86, 88].
The tracheobronchial region of the respiratory 
tract is covered with a viscoelastic blend contain-
ing glycoproteins, proteins, and lipids. However, 
the composition of this mucus may vary in case of 
diseases [91]. In testing conditions, an accurate 
simulation of in vivo parameters is continuously 
required. In dissolution testing, it can be achieved 
through the use of biological simulated lung flu-
ids (SLF), which serve as dissolution media.
The SLF was first developed by Moss in 1979 
[92]. This simulated fluid provides a greater com-
prehension of in vivo mechanisms. However, as 
seen previously, the development of a standard-
ized dissolution method is a complex project due 
to the special characteristics of the lungs, such as 
the particularly small volume of fluid present. 
Despite that, research was done to study a pos-
sible reproducible, standardized test method to 
investigate the dissolution profile of a micronized 
hydrocortisone pulmonary formulation. This 
method includes a dissolution test station (with 
mini-paddles, dissolution vessels, a water bath, 
and a sampling probe) and a membrane cassette. 
Among other things, the influence of the SLF com-
position on the dissolution rate was investigated. 
A modified version of the SLF (mSLF) was also 
used, which consists of 100 ml of SLF + 200 µg/mL 
of 0.02% (w/v) of dipalmitoylphosphatidylcholine 
(DPPC). The samples of hydrocortisone in SLF 
and mSLF were examined using an HPLC system. 
The mSLF yielded an increase in the release rate of 
hydrocortisone because a DPPC-containing medi-
um may enhance the wettability of hydrophobic 
drugs and inhibit the aggregation of particles, 
therefore increasing the dissolution rate [88].
Another study designed a biorelevant SLF with 
distinct composition and characteristics (Table V), 
as well as directions for usage and storage [93].
Conclusion
Overall, it has been established that the pulmonary 
drug delivery demonstrates a significant relevance, 
notably due to the physiology of the lungs and 
their advantageous properties. Despite the pres-
ence of some disadvantages such as clearance 
mechanisms, pulmonary drug delivery continues 
to be a non-invasive route of administration that is 
preferred by patients. It has also been shown that 
pulmonary delivery is one of the oldest drug deliv-
ery methods. Since its first use, its application has 
gotten more and more elaborated. Nowadays, sev-
eral types of inhalation devices are available on the 
market: nebulizers, MDIs, and DPIs. Supplementa-
ry devices such as spacers are also employable in 
order to achieve optimal results. The performance 
Table V Composition and characteristics of a simulated lung fluid (based on [93])
Composition Physicochemical parameters
Dipalmitoylphosphatidylcholine (DPPC)
Dipalmitoylphosphatidylglycerol (DPPG)
Cholesterol
Albumin
IgG
Transferrin
Antioxidants
pH=7.2
Viscosity = 1.138 x Pa.s
Conductivity = 14.5 ms
Surface tension = 54.9 mN/m
Density = 0.999 g/mL
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and effectiveness of such inhalation devices de-
pend partly on the particle size of the formulation 
used, as well as its deposition in the lungs. Such de-
position is achieved by several mechanisms: diffu-
sion, sedimentation, impaction, and interception. 
Furthermore, in order to assure the highest possi-
ble efficiency, formulations are developed follow-
ing several criteria. Therefore, thorough testing is 
required to ensure the safety and quality of the end 
product. These tests are performed on both the for-
mulation and the device which carries it. Investiga-
tions of the particle size and aerodynamic proper-
ties, for instance, can be done using laser diffrac-
tion and a cascade impactor.
Summing it up, the pulmonary drug delivery 
constitutes a considerably advantageous route of 
administration for local and systemic treatments 
of diseases. Nevertheless, the development of pul-
monary dosage forms is a complex process which 
requires extensive considerations and meticulous 
optimizing.
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1. Introduction
The group of anaerobic Gram-negative cocci 
(AGNC) includes the genera Veillonella, Mega-
sphaera, Anaeroglobus, Negativicoccus and Acidami-
nococcus [1]. These bacteria (with Veillonella species 
in the highest numbers among the members of 
the group) are an integral part of the microbiome 
of the oral cavity and the gastrointestinal, genito-
urinary and respiratory tracts of humans [1,2]. Be-
fore the advent of molecular methods (polymerase 
chain reaction) and novel diagnostic techniques 
in the clinical microbiology laboratories (e.g., 
mass spectrometry, sequencing), identification of 
anaerobic Gram-negative cocci was based solely 
on Gram stain morphology and anaerobic cultiva-
tion [2-5]. Awareness regarding the roles of anaer-
obes in various infectious diseases has increased 
in recent years, especially due to the pronounced 
interest towards the study of the human microbi-
ome; although the organisms mostly studied were 
Clostridium, Bacteroides, Prevotella, Fusobacterium 
species and Gram-positive anaerobic cocci (GPAC) 
[6-8]. There is a distinct lack of data and an uncer-
tainty regarding the prevalence and importance 
of AGNC species in human infections: these or-
ganisms are recovered in pure culture relatively 
infrequently, in addition, many laboratories do 
not have the suitable resources and equipment 
(e.g., GasPack jars, anaerobic glove boxes) for their 
isolation and identification [9,10]. The epidemiolo-
gy of different pathogens shows great variation 
among time periods and geographic regions 
therefore, the assessment of local data is essential 
to evaluate trends over time and to reflect on the 
national situation, compared to international 
data. The aim of this study was to assess and 
compare the prevalence of different species of 
AGNCs among inpatients and outpatients at the 
Albert Szent-Györgyi Clinical Center (Szeged, 
Hungary) retrospectively, during a 10-year study 
period.
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2. Materials and methods
2.1. Study design
The Albert Szent-Györgyi Clinical Center is an 
1,820-bed (1,465 active and 355 chronic beds, respec-
tively), primary and tertiary care university-affiliat-
ed (University of Szeged) teaching hospital, servic-
ing an urban and rural population in the southeast 
region of Hungary of about 405,000 people. 
Isolates containing AGNC were identified retro-
spectively by reviewing the online microbiology re-
cords of the Institute of Clinical Microbiology. The 
data screening included samples taken at inpatient 
departments and outpatient clinics over a 10-year 
period (January 2008–December 2017). In addition, 
patient data was also collected, limited to demo-
graphic characteristics (age, sex, inpatient/outpa-
tient status) and sample type. Isolates were consid-
ered separate if they occurred more than 30 days 
apart or different AGNCs were isolated [11,12].
2.2. Identification of isolates
The processing of samples arriving to the Institute 
of Clinical Microbiology was carried out according 
to guidelines in routine clinical bacteriology. The 
cultivation of anaerobic bacteria was carried out in 
line with principles in anaerobic bacteriology, at 
37°C in an anaerobic chamber (Baker Ruskinn, 
York, UK). Between 2008 and 2012, the identification 
of anaerobic isolates was carried out based the pre-
sumptive methods recommended by the Wad-
sworth Anaerobic Bacteriology Manual, additional-
ly, with the Rapid ID 32A (bioMérieux, Marcy-
l’Étoile, France) identification kit [13]. From 2013 on-
wards, identification was performed using matrix-
assisted laser desorption/ionization time-of-flight 
mass spectrometry (MALDI-TOF MS). Bacterial 
cells were transferred to a stainless-steel target us-
ing a sterile toothpick. An on-target extraction was 
performed by adding 1 ml of 70% formic acid prior 
to the matrix. After drying at ambient temperature, 
the cells were covered with 1 ml matrix HCCA (a-
cyano-4-hydroxycinnamic acid in 50% acetoni-
trile/2.5% trifluoro-acetic acid). Mass spectrometry 
measurements were performed by the Microflex 
MALDI Biotyper (Bruker Daltonics, Bremen, Ger-
many) in positive linear mode across the m/z range 
of 2 to 20 kDa; for each spectrum, 240 laser shots at 
60 Hz in groups of 40 shots per sampling area were 
collected [5]. The MALDI Biotyper RTC 3.1 software 
(Bruker Daltonics, Bremen, Germany) and the 
MALDI Biotyper Library 3.1 were used for spec-
trum analysis. Antibiotic susceptibility testing is 
not routinely performed from AGNC isolates [14,15].
2.3. Statistical analyses
Descriptive statistical analysis (including means 
or medians with ranges and percentages to char-
acterize data) was performed using Microsoft Ex-
cel 2013. Additional statistical analyses were per-
formed with SPSS software version 24 (IBM SPSS 
Statistics for Windows 24.0, Armonk, NY, IBM 
Corp.), using the χ2-test and Mann-Whitney’s 
U-test to compare groups. P values below 0.05 
were considered statistically significant.
3. Results and discussion
3.1. Study population
The median age of affected patients overall was 52 
years (range: 1–90 years), with a male dominance 
(56.64%, with male-to-female ratio of 1.31), which 
was present is most of the individual study years 
(Table I). 59.79% of samples originated from inpa-
Table I General characteristics of the study population (grouped by study year)
Study year 2008 2009 2010 2011 2012
No. of affected patients 19 29 27 21 39
Male-to-female ratio 2.17 1.23 0.80 1.33 0.74
Percentage of inpatients 57.89% 68.97% 48.15% 61.90% 58.97%
Median age [yrs] 55 50 47 56 52
Age range [yrs] (1-75) (6-87) (3-79) (18-90) (2-84)
 
Study year 2013 2014 2015 2016 2017
No. of affected patients 30 44 68 134 159
Male-to-female ratio 1.00 2.33 1.34 0.56 1.26
Percentage of inpatients 63.33% 65.00% 69.12% 63.43% 52.20%
Median age [yrs] 54 55 55 49 51
Age range [yrs] (11-83) (4-84) (1-86) (8-81) (7-83)
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tients. No statistically significant difference was 
observed between the patient characteristics (gen-
der, age, inpatient/outpatient status; p>0.05), how-
ever, a slight dominance of patients ≥50 years of 
age could be noted in both the inpatient and out-
patient groups (58.48% for inpatients and 63.63% 
for outpatients, respectively). 
Almost one-third of the samples originated 
from the Department of Otorhinolaryngology 
(29.29%); other major contributors to positive sam-
ples include the Departments of Surgery (16.07%), 
Internal Medicine 11.61%) and Oral Surgery 
(10.89%), while the remaining 32.14% of samples 
originated from nine other institutions (Table II).
31.45% of isolated GNACs originated from ab-
scess samples, while various wound isolates ob-
tained by invasive sampling methods (19.82%) or 
superficial swabbing (15.64%) were also prevalent. 
Other positive samples include bile specimens, 
puncture samples from the sinuses and inner ear, 
bronchoalveolar lavage, blood cultures and intra-
uterine devices (IUD) (33.09%). The composition of 
sample types that were positive for AGNCs is not 
surprising as most of these originated from ana-
tomical regions, where these bacteria as present as 
normal flora, in addition to being relevant patho-
gens, if there is an underlying pathology or surgi-
cal intervention in the patient’s anamnestic data.
During the 10-year study period, 572 individual 
AGNCs isolates were recovered from clinical sam-
ples at the Albert Szent-Györgyi Clinical Center. 
Most of the isolated GNACs were Veillonella spp. 
(95.28%), including V. parvula and V. atypica (corre-
sponding to more than half of the isolated species) 
as the most frequently isolated genera during the 
study period; in contrast, Megasphaera and Acidami-
nococcus species accounted for only a minority of 
isolates (2.79% and 1.93%, respectively), while An-
aeroglobus and Negativicoccus species were not iso-
lated (Table III). AGNCs were isolated as stand-
alone pathogens in only 32.87% of cases, they were 
mostly isolated together with other bacteria, as part 
of a complex aerobic/anaerobic flora. The number 
of isolated AGNCs was significantly higher in the 
period after 2013 (136 vs. 436 isolates; p<0.001). In 
the first half of the study period (2008-2012), most 
of the isolated pathogens were identified only at a 
genus level (78.83%), while in the second half of the 
study period (2013-2017), 91.31% of isolates were 
identified on the species level (p<0.001). 
4. Conclusions
The current study represents a long-term surveil-
lance study on the isolation frequency and trends 
among anaerobic Gram-negative cocci (AGNCs), 
isolated in the Southern Great Plain of Hungary 
over a 10-year period. To the best of our knowl-
edge, this is the first and longest-spanning study 
reporting on their prevalence (and infections 
caused by these pathogens by proxy) in Hungary. 
Based on the results of this retrospective survey, 
the most prevalent isolates at our tertiary-care cen-
ter were Veillonella spp. (which may be considered 
the anaerobic counterparts of Neisseria species), 
while other species in the group only represented 
a fraction of the isolated species; this is in line with 
the findings of the few studies available in the lit-
erature. Hospitalization, a slight male dominance 
and the age (>50 years) of many affected patients 
also correspond to literature findings [1-3,5,10]. 
There was a significant increase in both the num-
ber of isolated AGNC species and their correct 
(species-level) identification in the second half of 
the study period. Both may be explained by the in-
troduction of the MALDI-TOF MS identification 
system to the diagnostic workflow of the laborato-
Table II Origin of samples of interest at the Albert Szent-
Györgyi Clinical Center (SZTE)
Department/Clinic %
ENT 29.29
Surgery 16.07
Internal Medicine 11.61
Oral Surgery 10.89
Neurology   0.71
Obstetrics and Gynecology   3.21
Pediatrics   3.93
Dermatology   8.93
Intensive care   5.71
Emergency   1.61
Ophtalmology   0.36
Traumatology   5.71
Urology   1.96
ENT: Dept. of Otorhinolaryngology
Table III Species distribution among GNACs in the study 
period (2008-2017)
Veillonella spp.  545  (95.28%)
V. parvula  238  (41.60%)
V. atypica  103  (18.01%)
V. dispar  56  (9.79%)
V. denticariosi  5  (0.87%)
V. ratti  2  (0.35%)
Megasphaera spp.  16  (2.79%)
Megasphera muciniformis  10  (1.75%)
Acidaminococcus spp.  11  (1.93%)
Acidaminococcus intestinum  8  (1.39%)
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ry. Several studies have reported on the beneficial 
changed MALDI-TOF put forth in clinical micro-
biology, both in regard to the speed and the quali-
ty of identification [16]. This is especially true with 
anaerobic bacteria, as their cultivation and identi-
fication with conventional methods is time- and 
resource-consuming [5,9].
If we analyse these results from a clinical per-
spective, this would mean that 1-2 positive samples 
were received by the Institute of Clinical Microbiol-
ogy per week, where significant growth of AGNCs 
was detected. In these cases, the continuous com-
munication between physicians and the diagnostic 
microbiology laboratory is crucial. The role of the 
laboratory is to supply clinically relevant informa-
tion in a precise and timely manner, which should 
be reciprocated by the feedback of the physicians, 
beginning from the submission of the sample, fol-
lowed by information regarding the symptoms of 
the patient and the clinical picture [9]. 
Some limitations of this study must be acknowl-
edged. Firstly, the presence and nature of symp-
toms of the patients are unknown; additionally, 
due to the inability to access the medical records of 
the individual patients affected, the correlation be-
tween the existence of relevant underlying illness-
es (e.g., Type 2 diabetes, surgical interventions, iat-
rogenic or disease-related immunosuppression) 
and the infection could not be assessed. Further-
more, antimicrobial susceptibility testing of the 
isolated AGNC species was not performed, there-
fore no information is presented regarding the re-
sistance trends in the isolated bacterial strains.
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1. Introduction
Solubility is one of the most important molecular 
properties of drugs. It plays a key role in determin-
ing their absorption potential and has fundamen-
tal impact on the bioavailability therefore. Solubili-
ty data refers to the given physical form of a solid 
compound thereby it is significantly affected by 
polymorphism. Polymorphism – the ability of a 
substance to exist as two or more crystalline forms 
that have different arrangements and/or conforma-
tions of the molecules in the crystal lattice – is com-
mon among the pharmaceutical solids [1]. More 
than one third of drugs show polymorphism and a 
further one third is capable of forming hydrates 
and solvates [2]. This subject has gained intensive 
attention in both original and generic drug re-
search since in case of several drugs polymor-
phism caused serious safety problems [3]. The 
most known examples (from chloramphenicol pal-
mitate, through carbamazepine, oxytetracycline, 
enalapril, etc. up to ritonavir) have been extensive-
ly reported in the literature [4-8]. These cases in-
duced severe regulatory considerations [9] result-
ing that polymorph screening and the investiga-
tion of physico-chemical properties and stability of 
different polymorphic forms has become inevitable 
during the process of drug development [10, 11]. 
Polymorphs have different lattice energy so they 
differ in those physical and chemical properties 
which associated with the internal free energy of 
the solid, such as: density, refractivity, conductivi-
ty, hygroscopicity (packing properties); melting 
temperature, vapor pressure, solubility (thermody-
namic properties); dissolution rate, stability (kinet-
ic properties); and several others (surface, mechan-
ical, spectroscopic properties) [2]. From absorption 
and bioavailability point of view the solubility and 
the dissolution rate are the most relevant proper-
ties of a pharmaceutical compound, however from 
formulation and safety aspects stability is also es-
sential. A general rule is that a polymorph having 
the lower lattice free energy is the more stable form 
and it has the lower solubility while that having 
higher energy is less stable but tends to dissolve 
faster and has higher solubility [1]. Based on litera-
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Abstract
Aims: The aqueous solubility of two polymorphic forms of venlafaxine hydrochloride was investigated. 
Methods: The pH-dependent solubility (SpH) over a wide pH range was measured by saturation shake-flask (SSF) method at 25 °C. 
The solubility of the free base form was depicted by the intrinsic solubility (So). To identify the solid form present at the solubility equi-
librium, X-ray powder diffraction (XRPD) and Raman spectroscopy was carried out. The dissolution was studied using real time con-
centration monitoring applying fiber optic UV probes. 
Results: No difference was found in the SpH values of Form I and Form II, in the pH range 7.5-12. Solid phase isolated from pH 10-12 
suspensions was identified as free base by XRPD and Raman spectroscopy. Precipitates separated from pH 7-8 samples were also iden-
tical product. The transition of polymorphs to the free base was supported by the real time dissolution analysis. 
Conclusion: In this study we demonstrated a good agreement of equilibrium solubility measured by SSF method and in-situ UV fiber 
optic method. µDISS ProfilerTM has the advantage to provide much more information about dissolution process; with this approach the 
dissolution kinetic, the supersaturation and the time needed to reach the equilibrium can be easily monitored. 
Keywords: solubility-pH profile, polymorphs, shake-flask method, µDISS Profiler, venlafaxine
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ture solubility data Pudipeddi and Serajuddin [12] 
published a survey that the ratio of metastable/
stable polymorph solubility is typically less than 
2, though occasionally higher ratios can be ob-
served as reported for sulindac (7x difference be-
tween From I and II) [13] and for premafloxacin 
(23x) [14], etc. Similar trend was found for anhy-
drate/hydrate solubility ratio (~2) with many ex-
ceptions, while the amorphous/crystalline forms 
solubility differs with factor ~10, generally. Solu-
bility difference of polymorphs will have effect on 
the bioavailability/bioequivalence (BA/BE) of a 
drug product if the solubility is the rate limiting 
factor upon absorption (for BCS II and IV drugs). 
Solubility characterized by the equilibrium sol-
ubility data is the concentration of the compound 
in a saturated solution when solid and solute are 
at equilibrium. This parameter can be measured 
by several methods however the “gold standard” 
is still the saturation shake-flask technique (SSF). 
Recently Avdeef et al. published a consensus-
based “white paper” commentary which summa-
rized the recommendations for solubility mea-
surement including SSF and other methods to im-
prove the data quality [15]. The paper pointed out 
to the difficulties in the measurement of poly-
morphs due to the possible polymorph transi-
tions upon equilibration and the importance of 
the analysis of both solution and solid phases. 
Well established methods for solid phase analysis 
(X-ray powder diffraction XRPD, differential 
scanning calorimetry DSC, FT-IR and Raman 
spectroscopy, etc.) should be used for character-
ization of the solid at the beginning and also at 
the end of the solubility experiment. Adhering 
and applying all these recommendations of the 
“white paper” one can measure only the thermo-
dynamic solubility of that crystalline form which 
is in dynamic equilibrium with its solution form, 
at the temperature of the experiment. However, 
during the dissolution process polymorphs can 
show different kinetics, resulting in substantially 
various supersaturation solutions even so if later 
they convert to another form. The incubation time 
in the standard protocol of SSF is 24 h (6 h agita-
tion and 18 h sedimentation) [16]. Since solvent 
induced changes in solid form structure might oc-
cur much faster or slower than this timeframe the 
in situ monitoring of the dissolution-time profile 
may provide more information about the behav-
ior of polymorphs and may enable the optimiza-
tion of incubation time. Moreover in situ monitor-
ing with fiber optic UV probes under certain con-
ditions (low amount of excess solid, long analysis 
time, etc) enables the determination of dissolution 
kinetics and also equilibrium solubility from a 
single experiment. 
The goals of the present study were: (1) investi-
gation of equilibrium solubility of different poly-
morphs of venlafaxine hydrochloride (VENL) as 
model compound, in wide pH range by SSF 
method coupled with solid phase analysis; (2) 
real time monitoring of the dissolution profile us-
ing in situ UV fiber optic; (3) to compare the equi-
librium solubility results obtained by SSF and 
µDISS methods and (4) to reveal the advantages 
and limits of the latter technique for solubility 
measurement.
2. Material and methods
2.1. Materials
The structure of model compound is presented in 
Figure 1. Venlafaxine hydrochloride (313.86 g/mol) 
was purchased from Sigma-Aldrich Co. LLC. (St. 
Louis, MO, USA). From the commercially avail-
able polymorph the other polymorphic form was 
prepared in house based on patent (US6924393B2) 
and verified by XRPD. Distilled water of Ph. Eur. 
grade was used. All other reagents were of analyt-
ical grade. 
A Britton-Robinson (BR) buffer stock solution (a 
mixture of acetic acid, phosphoric acid and boric 
acid, each at 0.04 M) was prepared, and the re-
quired amount of 0.2 M NaOH or 1M NaOH was 
added to give the pH specified for the solubility 
experiments. BR buffer solutions were used in pH 
range 7.5-11, while at pH 11 and above NaOH was 
applied.
Figure 1 Structure of venlafaxine hydrochloride
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2.2. Determination of the thermodynamic solubility by 
saturation shake-flask method (SSF)
2.2.1. Preparation of saturated solution
The equilibrium solubility of VENL in the exam-
ined pH region was determined by the SSF meth-
od [16, 17]. The sample was added in excess to the 
aqueous buffer solutions to produce a suspension. 
The amount of solid added was accurately mea-
sured: 10-300 mg/4 mL. At controlled temperature 
of 25.0 ± 0.1 °C the solution containing solid excess 
of the sample was vigorously stirred for a period 
of 6 h (agitation time), what followed a further 18 h 
of sedimentation period (stirrer turned off).
 2.2.2. Concentration determination of the saturated 
solution
2.2.2.1. Off-line: sampling, dilution and concentration 
measurement with UV spectrophotometer
The concentration of the saturated solution was 
measured by UV spectroscopy using JASCO V 550 
UV/VIS spectrophotometer. Three aliquots were 
carefully withdrawn from the liquid, using a fine 
glass pipette, and were diluted with the solvent if 
necessary. Three replicate solubility measure-
ments were carried out at each of the tested condi-
tions. 
The specific absorbance (A1%1cm, the absor-
bance of 1 g/100 mL solution over a 1 cm optical 
pathlength at a given wavelength) of VENL was 
determined separately at pH 8.0 using 12 points 
of two parallel dilution series, from the linear 
regression equation (Lambert-Beer law) where 
the regression coefficient (r) was higher than 
0.9998. The specific absorbance data obtained is 
38.4 at λmax 273.5 nm. This value was used for 
concentration calculation at all pHs since the 
UV spectrum of VENL is not pH-dependent 
due to the distance between the protonation site 
(aliphatic N atom) and the chromophore in the 
structure. 
2.2.2.2. In situ: with fiber optic UV probe
µDISS ProfilerTM (Pion Inc. Billerica MA, US, Figure 2) 
has been applied as UV fiber optic instrumenta-
tion. The equilibrium concentration was concomi-
tantly determined in situ in the equilibrated solu-
bility suspension (without dilution) immersing the 
UV dip probe. Calibration was performed with 
the same (2-5-10-20 mm) tip adjusted to the fiber 
optic UV dip probe which was used in the given 
solubility experiment. Solubility values obtained 
from the same experiments analysed with both 
the off-line and the in situ UV method were com-
pared (see section 3.3.).
2.3. In situ real time monitoring of dissolution, 
supersaturation, precipitation and the equilibrium 
solubility
The drug solution concentration versus time (0-24 h) 
was investigated with the µDISS ProfilerTM. The in-
strument measures the real time concentration 
with fiber optic UV dip probe inserted in 6 tem-
perature controlled 20 mL vessels, stirred with 
magnetic stirrer. Dissolution of VENL was regis-
tered in BR buffer pH ~ 11.5, in three parallel chan-
nels, where 10 mg sample was added to 4 mL dis-
solution media. Using the appropriate 2 mm  tip 
adjusted to the UV probe, the UV spectra were 
registered in the following timing protocol: per 
1 min in 0-2 h, per 10 min in 2-6 h and per 30 min 
in 6-24 h periods. The stirrer was turned off at 6 h. 
For the evaluation of the concentration previously 
determined calibration data and second derivative 
spectra were used. 
2.4. Methods for the analysis of the solid phase
2.4.1. XRPD
Small amount of the solid phase at the end of solu-
bility measurement was isolated and dried to a 
glass plate. X-ray powder diffraction patterns of 
these samples were recorded by means of a 
PANaly tical (Amelo, The Netherlands) X’pert 
ProMDP X-ray diffractometer using Cu-K”α radia-
tion (1.524 Ǻ) and a Ni filter. The applied voltage 
Figure 2 µDISS ProfilerTM
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was 40 kV, while the current was 30 mA. The sam-
ples were analysed between 4° and 42° 2θ.  
2.4.2. Raman spectroscopy
Raman spectra were collected using a Horiba Jobin-
Yvon LabRAM system coupled with an Olympus 97 
BX-40 optical microscope (Olympus Corporation, 
Tokyo, Japan). The sample was illuminated by a 
785-nm diode laser (TEC 510 type, Sacher Laser-
technik, Marburg, Germany) and an objective of ×10 
(laser spot size, approximately 4 µm) was used for 
optical imaging and spectrum acquisition. The laser 
beam is focused through the objective, and the 
backscattered radiation is collected with the same 
objective, a common configuration found in most 
confocal spectroscopic systems. The collected radia-
tion is directed through an edge filter that removes 
the Rayleigh photons and then through a confocal 
hole (500 µm) and the entrance slit (100 µm). Finally, 
a 950 groove/mm grating monochromator disperses 
the Raman photons before reaching the CCD detec-
tor. Each spectrum of the image was collected in the 
spectral range of 300 to 1600 cm−1.
2.4.3. Polarized light microscopy
Polarized light microscopic images were taken us-
ing Amplival (Carl Zeiss, Jena, Germany) type mi-
croscope coupled with Olympus C4040 Z type 
camera (Olympus, Japan).
2.5. Statistical analyses
Concentrations were expressed as means ± SD, 
and were compared using “two-sample” Student’s 
t test. Differences were considered statistically sig-
nificant when p < 0.05.
3. Results and Discussion
In this study we measured the equilibrium solu-
bility of different polymorphic forms of venlafax-
ine hydrochloride modelling the possible behav-
iour of a pharmaceutical solid. The pH-dependent 
equilibrium solubility (SpH) over a wide pH range 
was investigated by SSF method at 25 °C tempera-
ture. The solubility of the free base form was de-
picted by the intrinsic solubility (So) measured at 
high pH value. To identify the solid form that is 
present at the solubility equilibrium, the approach 
was completed with the solid phase analysis at the 
end of the solubility experiment. We also studied 
the dissolution kinetics and the extent of supersat-
uration and the incubation time needed to reach 
the equilibrium, using real time monitoring by 
µDISS ProfilerTM to reveal the differences between 
the stable and less stable/metastable forms. 
Venlafaxine is a 2nd generation, SNRI (serotonin-
norepinephrine reuptake inhibitor) antidepressant 
drug nowadays widely used in depression, in gen-
eralized anxiety disorder, post-traumatic stress dis-
order, etc. (US Patent, 2006, US7030164B2). VENL 
is used as racemate of its hydrochloride salt which 
is known to exist in two polymorphic forms, Form 
I and Form II. Though Form I is more stable (melt-
ing temperature: 210-212 °C, ΔH: 125.8 J/g) than 
Form II (melting temperature: 208-210 °C, 
ΔH: 130.3 J/g) the latter is preferred in the formula-
tion because it has larger particle size with better 
filtration and drying characteristics [18]. VENL is a 
monovalent base (pKa: 9.63), its solubility is pH-
dependent. Since the compound belongs to BCS I 
class, the solubility is not an absorption limiting 
factor from GI tract. Investigation of salt solubility 
in biorelevant medium was not the goal of this 
study. However VENL is a good model for study-
ing the pH-dependent solubility of polymorphs 
and for comparison the SSF and µDISS methods in 
the measurement of intrinsic solubility. 
Table I Equilibrium solubility of venlafaxine hydrochloride 
polymorphs in BR buffer measured by SSF method
VENL Form I VENL Form II
pH SpH ± SD
 (mg/mL)
n pH SpH ± SD
(mg/mL)
n
7.50 59.35 ± 8.23 9 7.54 54.32 ± 4.43 3
7.70 32.08 ± 2.60 9 7.60 45.67 ± 2.34 9
7.83 23.34 ± 0.45 3 7.67 38.35 ± 2.99 9
8.30 8.655 ± 0.267 9 7.78 26.79 ± 0.27 3
8.34 7.194 ± 0.043 3 8.20 8.175 ± 1.061 9
8.37 7.495 ± 0.601 3 8.40 7.689 ± 0.345 9
8.43 6.983 ± 0.103 3 8.52 5.506 ± 0.104 3
8.47 6.364 ± 0.071 3 8.58 4.985 ± 0.053 3
9.30 0.948 ± 0.031 9 8.64 4.587 ± 0.013 3
9.50 0.796 ± 0.094 9 8.70 3.809 ± 0.104 3
9.72 0.574 ± 0.011 3 9.45 0.831 ± 0.027 9
9.76 0.507 ± 0.004 3 9.76 0.567 ± 0.014 4
9.81 0.559 ± 0.062 3 9.96 0.544 ± 0.011 3
9.96 0.570 ± 0.013 3 10.06 0.495 ± 0.052 4
10.34 0.521 ± 0.186 3 10.26 0.523 ± 0.037 4
10.41 0.454 ± 0.011 3 10.41 0.498 ± 0.034 4
11.51 0.275 ± 0.004 4 11.62 0.296 ± 0.025 4
12.11 0.292 ± 0.007 4 12.01 0.285 ± 0.004 4
Concentration is expressed as free base equivalents. 
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3.1. Solubility-pH profile of venlafaxine polymorphs
The equilibrium solubility of VENL Form I and II 
were measured by the standard protocol of SSF 
method at 18 different points in pH range 7.5-12, at 
25 °C. The SpH ± SD results are expressed in mg/mL 
unit as average value of parallel measurements and 
are presented in Table I. The standard deviation was 
in the range of 1-13 %, average SD: 6 %. No signifi-
cant difference was found between the SpH values 
of polymorphs at the same pH in the whole exam-
ined region. This can be interpreted with the tran-
sition of polymorphs to a common product as sup-
ported by the solid phase analysis (see below 3.2). 
Figure 3 shows the solubility-pH profile of 
VENL Form I and Form II as plotted logS [M] val-
ues vs pH. As it can be seen in Figure 3 the curve is 
typical for a monoprotic base as described by the 
theoretical Henderson-Hasselbalch (HH) relation-
ship (logS = logS0 + log(10
pKa-pH + 1) [17, 19]. 
The intrinsic solubility of VENL base (calculat-
ed as the average of values measured at pH ≥ 11.5) 
is logSo [M]: -2.93 ± 0.014 (n=4). This value was 
used to generate the HH curve of VENL (solid line 
on Figure 3). The experimental data points closely 
follow the theoretical HH curve. Below pH 10 the 
VENL free base starts to convert to cationic form 
and the solubility is increasing. Below pH 7 the 
solubility was not studied because the salt solubil-
ity is very high (> 500 mg/mL) and its saturated 
solution can be considered non-ideal solution.
3.2. Characterization of the solid phase isolated from 
solubility experiment
First the starting materials, Form I and Form II 
were identified by powder X-ray diffraction (see in 
Figure 4). Next the samples isolated and dried 
from the solubility suspension after incubation at 
different pHs were studied. Diffractograms shown 
representatively in increasing pH order in Figure 4 
demonstrate that the samples are not identical 
with the starting polymorphic forms in neither 
case. Results indicate that both polymorphs re-
Figure 3 Solubility-pH profile of VENL Form I and Form 
II (solid line represents the theoretical HH curve calculated 
from pKa: 9.63 and logSo: -2.93, points represent the 
experimental data)
Figure 4 XRPD patterns of VENL Form I and Form II and the solids isolated from solubility suspensions  
at different pH values
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crystallized to a common form. Product obtained 
at lower pHs (7.5-9) could not be identified using 
Cambridge Structural Database. Based on patent 
US20030114536A1 we identified the product as 
venlafaxine hydrochloride monohydrate. Patterns 
registered at higher pH (11-12) values were found 
identical with one of the free base VENL poly-
morphs, specified in the database as free base 
Form I. A peak (if any) appeared with various in-
tensity in the patterns of free base at 9 (2 Theta) is 
due to the presence of sodium acetate remained in 
some samples. XRPD finding was supported by 
Raman spectroscopy as well (Figure 5). The polar-
ized light microscopic images in Figure 6 (A and B 
panels) indicate that crystal shape of Form I and II 
is column but they substantially differ in their 
size. Panel C shows the shape of the free base 
form isolated at pH 12. 
All above results of solid phase analysis con-
firm and can interpret the equilibrium solubility 
data measured experimentally (Table I) in pH 
range 7.5-12. 
3.3. Comparison of concentration measurement with 
off-line UV method and in situ UV probe
µDISS ProfilerTM measures the concentration of the 
solute in situ in the saturated solution in the pres-
ence of solid. In order to prove that it has no im-
pact on the results (e.g. distorting the absorption 
measurement), in a part of SSF experiment at the 
end of incubation time the concentration of the 
saturated solution 
was measured by 
two ways: (1) after 
the necessary dilu-
tion with tradition-
al UV spectropho-
tometer (UV-JAS-
CO), and (2) in situ 
in the solubility 
vessel (without di-
lution) by UV 
probe (UV-µDISS). 
Solubility values 
shown in Table II 
are in good agree-
ment. Difference 
between the results 
Figure 5 Raman spectra of solid phase of VENL polymorphs isolated from solubility suspensions
Figure 6 Polar microscopic images of VENL samples (A: Form I, B: Form II, C: free base isolated at 
pH 12)
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varies in 0.2-15%, average is about 5%. It can be ob-
served that in 7/10 cases µDISS measures the low-
er value. 
3.4. Real time monitoring of dissolution by µDISS 
ProfilerTM
The real time dissolution profile was monitored 
by µDISS ProfilerTM. It was performed in BR buffer 
pH ~11-11.5 (exact pH was measured at the end of 
the experiments) in 0-24 h period, where in the 
first 6 h stirrer was turned on. The UV spectra 
were registered according to a protocol (see in sec-
tion 2.3.) in three parallel vessels and the concen-
tration was calculated using calibration. Figure 7 
shows that dissolution process of VENL can be 
followed well and the equilibrium solubility can 
Figure 7 Solubility-time profile of VENL Form I (upper panels) and Form II (lower panels) at pH ~ 11.5 in BR buffer 
monitored by µDISS approach
Table II Equilibrium solubility of venlafaxine hydrochloride 
polymorphs measured by SSF method using different 
concentration detection
Sample
VENL pH
SpH ± SD (mg/mL)
UV-JASCO UV-µDISS
Form I
7.50 59.35 ± 8.23 56.98 ± 6.89
7.70 32.08 ± 2.60 31.34 ± 2.40
7.83 23.34 ± 0.45 22.44 ± 0.31
9.30 0.948 ± 0.031 1.121 ± 0.038
9.50 0.796 ± 0.094 0.764 ± 0.080
Form II
7.54 54.32 ± 4.43 48.51 ± 6.32
7.60 45.67 ± 2.34 45.54 ± 1.25
7.67 38.35 ± 2.99 36.49 ± 0.45
7.78 26.79 ± 0.27 26.96 ± 0.40
9.45 0.831 ± 0.027 0.853 ± 0.030
Concentration is expressed as free base equivalents. 
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also be measured by this approach. In case of 
Form I (Figure 7 upper panels) the supersaturation 
is very similar in the three parallel experiments 
and solute reaches 3.5 times concentration relative 
to the equilibrium solubility. Precipitation starts at 
different time in the parallels (12-25-30 min, re-
spectively) and the samples are reaching the equi-
librium in rather short time (20-40 min). The con-
centration is not changing further when at 6 h 
stirrer is turned off up to 20 h. A small (~13%) in-
crease in concentration can be observed in 20-24 h 
period for one of the channels. It may be due to 
the adsorption of solid crystals to the UV probe 
without stirring of the suspension. The dissolu-
tion-time profile of Form II as starting material 
(Figure 7 lower panels) is very similar. It reaches a 
bit slower the same supersaturation as Form I but 
the precipitation and time needed to reach the 
equilibrium is the same. We can conclude from 
this profiling that VENL polymorphs are convert-
ing to the common free base form immediately af-
ter dissolution. Intrinsic solubility measured by 
µDISS ProfilerTM at 24 h is 0.290 ± 0.004 mg/mL 
(logSo [M]: -2.98) (n=4), it perfectly agrees with So 
obtained by SSF method. 
4. Conclusions
In this study we have demonstrated the impor-
tance of solid phase analysis in the solubility in-
vestigation of drug polymorphs giving reliable in-
formation about which form is present in solubili-
ty equilibrium. We presented an example for the 
possible behavior of pharmaceutical compounds. 
Venlafaxine hydrochloride Form I and Form II 
transformed to a common product in aqueous 
buffer solution in pH 7.5-12 region and thus the 
measured solubility values at a given pH were 
identical. Solid isolated from pH 10-12 was identi-
fied as the free base, while between pH 7-8 the iso-
lated common product was identified as VENL 
hydrochloride monohydrate based on XRPD re-
sults. Since VENL dissolves freely in acidic medi-
um not the solubility but the better manufactur-
ability can explain why the less stable Form II is 
preferably used in tablets.
We have also presented the good agreement of 
equilibrium solubility measured by SSF coupled 
with off-line analytics and in situ fiber optic con-
centration monitoring. µDISS ProfilerTM has the 
advantage to provide much more information 
about dissolution process, with this approach the 
dissolution kinetic, the supersaturation and the 
time needed to reach the equilibrium can be easily 
monitored. It is simpler and occasionally can be 
faster than traditional methods however there are 
limits of its application. Neither too high nor too 
low solubility can be measured with this instru-
ment, the optimal solubility window is about 
1-500 µg/mL. Since the new APIs in drug research 
are mainly poorly soluble compounds, for their 
solubility study µDISS Profiler seems to be advan-
tageous. 
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